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ABSTRACT
A review of patients who underwent a hydrogen breath test for Small Intestinal
Bacterial Overgrowth, following an oesophagectomy or gastrectomy was
carried out in the Gastrointestinal Function Unit, St. James’s Hospital, Dublin.
The aim of this research was to look at the incidence of Small Intestinal
Bacterial Overgrowth and create an optimal protocol for Hydrogen Breath
Testing with the hope of improving patient compliance and reducing clinic
waiting times. Factors such as lifestyle, multimodal therapy, tumour
morphology, and gender were analysed in relation to positive Hydrogen
Breath Test results in this patient group. Patients were selected following a
referral from the upper GI Surgical team. Exclusion criteria included those
patients whom had complicated upper major GI surgery, those patients that
had their surgery for a non-malignant carcinoma, and those patients that had
their surgery for achalasia or a gastric fistula.
Following a strict 12 hour fast and following pre-procedure instructions, the
patient’s hydrogen breath test was conducted. A preliminary mouth rinse with
a chlorhexadine agent was performed followed by a baseline breath sample.
A solution of glucose or fructose was consumed and samples were taken
every 15 minutes over a two hour period. The patient performed this
manoeuvre by holding their breath for approximately 10 seconds and exhaling
into the Gastro+ Gastrolyzer® breath monitor. Values were measured in parts
per million.
Poor lifestyle factors did not have an effect on the outcome of Hydrogen
Breath Test results. Those patients who had a history of previous malignancy
and post-operative complications showed a higher tendency towards a
positive glucose Hydrogen Breath Test result as did those patients who had a
longer post-operative hospital stay. This however, was not statistically
significant. The percentage of patients who were positive for Small Intestinal
Bacterial Overgrowth (53% in total) was greatest 6-12 months post-surgery.
This may be attributed by the fact that intestinal motility including Migrating

Motor Complexes can take up to 12 months before it is restored to its normal
functioning state. The positive patient group tested using glucose substrate
demonstrated a 93% positivity for SIBO at 60 minutes. Therefore, this
suggests that altering the protocol of testing from 2 hours to 60 minutes
should be considered
Some patients (up to 10%) are non-hydrogen producers, those who are very
symptomatic with negative Hydrogen Breath Tests should be considered for
bile acid malabsorption investigation using SeHCAT (tauroselcholic [75
selenium] acid). SeHCAT is now available in St. James’s hospital to
investigate patients who are symptomatic with steatorrhoea/diarrhoea postsurgery. Small Intestinal Bacterial Overgrowth can be the cause of bile acid
malabsorption, therefore it should be considered to treat it with antibiotic
therapy and assess clinical response before commencement with prescribed
bile acid sequestrants.
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Chapter 1
1 Introduction

Hydrogen Breath Testing (HBT) is a technique that is directly and
instantaneously capable of detecting both small intestinal bacterial overgrowth
(SIBO) and dietary malabsorption. It is a simple and non-invasive procedure
with few cost implications. The patient attends the Gastrointestinal Function
unit after adhering to strict pre-procedure guidelines and the specific substrate
(glucose, lactulose, or fructose) dissolved in 250mls of water is consumed.
The patient is asked at regular intervals of 15 minutes to exhale into the
Gastro+ Gastrolyzer® (Gastro+ Operating Manual 2014) HBT machine and a
direct read out of Hydrogen in exhaled breath is measured in units of parts per
million (ppm). Depending on the values obtained and the substrate consumed,
this procedure can take from 90-180 minutes to perform.
Small intestinal bacterial overgrowth, malabsorption of Lactose, Sucrose and
Fructose, and Intestinal transit time using Lactulose can all be measured
using the HBT. Glucose and Lactulose are the most commonly documented
substrates used for detecting SIBO (Simren and Stotzer 2006).
Small intestinal bacterial overgrowth (SIBO) is as the name suggests a
bacterial overgrowth within the small intestine. Normally, anaerobic colonic
bacteria reside in the large intestine and perform multiple functions to regulate
the digestive system. Sometimes, conditions within the gastrointestinal (GI)
tract prohibit the defence mechanism to prevent and keep bacterium from
colonising within the small intestine. This may include elevated pH within the
stomach, dysrhythmic activity altering the intestinal motility, or following GI
surgery (DiBaise 2008).
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When SIBO is present, the bacteria compete with the normal digestive
process and affect the method in which nutrients pass across the lumen of the
small intestine. The bacteria essentially ‘eat’ the nutrients (particularly
carbohydrates and sugars) entering the intestine and produce by-products as
a result. These include gases such as carbon dioxide and hydrogen, and
short-chain fatty acids (Eisenmann et al 2008). It is these by-products that can
cause unpleasant abdominal and GI symptoms such as bloating, flatulence,
epigastric and abdominal pain, nausea, early satiety, and altered bowel habit.
Patients who complain of such symptoms are often referred to have SIBO
investigations performed.
The rate of positive results in the GI function unit when testing for SIBO, is
overall quite low. During a data analysis of procedures performed over a two
year period, one group of patients with a high positive result for SIBO was
evident. This was a surgical group of patients who was referred to the GI
function unit post oesophagectomy or gastrectomy that were now complaining
of post-surgical symptoms such as those described above in conjunction with
malabsorption issues.
The HBT does not impose any discomfort or agitate the patient in any invasive
or unwarranted way. Side effects are uncommon and would include those
symptoms listed above i.e. the patients’ normal symptomatic response to
SIBO. In rare circumstances, patients’ may experience dizziness, allergy-like
reactions or tachycardia arrhythmias (Ledochowski M and Ledochowski E
2008). The drawback of this investigation for the patient is the time it takes to
perform this study, compliance with the pre-procedure instructions and
travelling for their appointment.
In response to the above results, a retrospective study was undertaken on
post-surgical patients that were referred to the unit, to investigate the
incidence of SIBO. The aim was to determine at what point might SIBO have
developed in these patients; and whether factors such as neoadjuvant
chemotherapy or radiotherapy, the location of cancer/tumour, previous history
of carcinoma, or surgery on the GI tract influenced the development of SIBO.
2

A comprehensive data analysis of e.g. patient history, lifestyle, co-morbidity
factors, complications post-surgery and hydrogen breath test results, was
scrutinised to determine if there was a significant aspect or consequence that
could result in a greater incidence of developing SIBO.
Factors related to the optimal timing of HBT sampling in post-surgical patients
were examined to determine at which point patients were most likely to show
a positive result. The overall aim of the present study is to create an optimal
protocol for HBT in patients following GI surgery. This is to include the time
segments between sampling, so that crucial values of exhaled Hydrogen are
not missed due to altered GI physiology.
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Chapter 2
2 Anatomy and Physiology
2.1

Gastrointestinal Tract

The GI system consists of the mouth, oral cavity, oesophagus, stomach, small
intestine, large intestine, rectum and anus, refer to Figure 2-1. (Martini 2006).
The liver and pancreas are associated digestive organs which produce and
secrete digestive juices into the small intestine.

Figure 2-1 - Anatomy of the GI Tract (Visionary Health 2014)
The oesophagus consists of striated muscle in the proximal segment and
smooth muscle in the distal two thirds. It is approximately 25 cm in length with
two sphincters; the upper oesophageal sphincter (UOS) in the proximal
oesophagus and the lower oesophageal sphincter (LOS) in the distal
oesophagus. The function of sphincters is to control the direction of flow
through the GI tract (Stendal 1997).
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The stomach has five main functions; to act as a reservoir for ingested food,
to mix and grind food, to chemically break down food, to kill ingested
microbes, and to control the emptying of gastric contents into the duodenum.
The stomach has a number of important functions as described in Table 2-1
overleaf.
The motility of the stomach and small intestine differs depending on whether a
person is fasting or has eaten recently. Migrating motor complexes (MMC) are
the dominant pattern in the fasting state. Following ingestion of a meal, MMC
are replaced by peristaltic and segmenting and mixing waves (DLGIP 2009).
The pacemaker located on the greater curvature (refer to Figure 2-2) of the
corpus of the stomach generates electric impulses for gastric motility. These
are intense contractions that encourage mixing and grinding of solid food.
There is a lag phase of about 30-60 minutes after eating before food is
emptied into the duodenum.

Figure 2-2 - Regions of the Stomach
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Table 2-1 - Function of the main regions of the stomach
Region

Function

Cardia

Joins stomach and oesophagus

Fundus

Main Reservoir where ingested food is received

Corpus

HCL and pepsin produced here as well as fundus. Pacemaker
area of stomach is located on the greater curvature of corpus

Antrum

Hormone gastin is produced here. There is no HCL secretion in
this part. Principal site where solid food particles are ground
down before emptied into duodenum

Pylorus

Controls emptying of food into duodenum and limits regurgitation
of duodenal contents back into stomach.

The small intestine is approximately 3-5m in length and consists of the
duodenum, jejumum and ileum. The main function of the small intestine is the
digestion and absorption of nutrients. This is implemented through (1) the
mixing of food with digestive juices secreted into the intestinal lumen (2)
ensuring the products of digestion come into contact with the absorptive
surface of the small intestine and (3) to propel any waste products towards the
colon (Stendal 1997). The duodenum is the most proximal portion of the small
intestine. It is also the shortest part and extends from the pylorus, around the
head of the pancreas and down to the jejunum. The common bile and
pancreatic duct which open into the duodenum, allow bile and pancreatic
juices to enter this portion of the intestine. The sphincter of Oddi controls the
release of these digestive juices into the duodenum (Stendal 1997).
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The colon has many functions, the most important of which are; the
absorption and secretion of certain electrolytes and water, and the storage
and excretion of waste (Gibson and Roberfroid 1995). The large intestine is
approximately 1.3m in length and consists of the cecum with its appendix,
ascending, transverse, descending and sigmoid colon (Stendal 1997). The
ileocecal valve is at the junction of the ileum and cecum and prevents
retrograde movement of colonic contents back into the small intestine. It also
regulates entry of small intestinal content into the colon.
The colon at birth is a sterile, dark, warm, moist and anaerobic tract. It rapidly
fills with food and the above conditions make it an ideal environment for
bacteria to grow, therefore rapid colonisation occurs. A gram of caecal content
may comprise of 400-500 species of bacteria and up to 2 billion organisms
from 17 different bacterial families creating a microbial ecosystem (Chapman
2001). There is a balance between the colonic bacteria and colonic
epithelium. If this balance is altered, diarrhoea may result because the colonic
epithelium is unable to effectively absorb sufficient quantities of water. This
can occur for example as a result of antibiotic therapy and separately, if there
is an immune response to the colonising bacteria, mucosal inflammations can
occur. This results in diseases such as ulcerative colitis. Finally, if the bacteria
cross invasively through the colonic epithelium, sepsis can develop (Chapman
2001).
The gallbladder acts as a reservoir for bile and holds around 20mls of bile
juice. Bile is transported from the liver to the gallbladder via the hepatic and
cystic duct. The main function of bile is to emulsify fats. It is released in
response to hormones secreted by the duodenum, usually in the presence of
meals (Stendal 1997). Bile is transported to the duodenum via the cystic and
common bile duct. The pancreatic duct is connected at the distal region to the
common bile duct where the united channel in most cases empties into the
duodenum. The sphincter of Oddi is located here, the function of which is to
regulate the entry of pancreatic and bile juice into the duodenum (Stendal
1997).
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The pancreas houses two major cell types; exocrine and endocrine. The
function of the endocrine cells is the production of insulin, glucagon, and
somatostatin which mainly regulate blood sugar levels. The exocrine cells
produce and secrete digestive enzymes and bicarbonate ions. With regards to
pancreatic secretion, hormonal mediators are more important than neural
mechanisms for stimulation of pancreatic juices.
Carbohydrates and fats are the body’s main source of energy. Most dietary
carbohydrates are in the form of large polysaccharides or disaccharides. In
order for these sugars to be absorbed, they must be metabolised by enzymes
into their monosaccharide absorbable forms (Simren and Stotzer 2006).
Glucose and fatty acids are the main substances metabolised for use by the
Krebs cycle to produce energy. The Krebs cycle occurs within the
mitochondria of a cell (Martini 2006).
Monosaccharide’s have a ring-shaped structure. They are single-sugar units.
Disaccharides are formed from two monosaccharide molecules that are
bonded together; examples include Lactose, Sucrose and Maltose (Martini
2006). Both monosaccharide’s and disaccharides contain only one or two
sugar units and so are referred to as simple carbohydrates (Nix 2012).
Polysaccharides are long chains of monosaccharide molecules. Examples
include starch and glycogen (Martini 2006). They are referred as complex
carbohydrates (Nix 2012).
Because monsaccharides are single molecules, they do not need be
metabolised and so are readily absorbed across the small intestine.
Disaccharides on the other hand need enzymes to break the bond between
the molecules. Examples include the lactase enzyme which metabolises
lactose into glucose and galactose. Another example is the sucrase enzyme
which metabolises sucrose into its monosaccharide components glucose and
fructose.
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As polysaccharides are more complex structures, metabolism occurs at a
much slower rate. Because of this mechanism, energy is released over a
longer period of time (Nix 2012).
The physiological effects of carbohydrates apart from energy supply to the
biological system includes; the control of blood glucose and insulin
metabolism, satiety and gastric emptying, cholesterol and triglyceride
metabolism, bowel function, bile acid dehydroxylation and they also affect
colonic micoflora (FAO 1997).
Salivary amylase begins the process of carbohydrate digestion. Mastication of
food mixes the bolus with saliva and the enzyme amylase initiates the
hydrolysis of starch (digestible carbohydrate). Salivary amylase is deactivated
by the low pH of the gastric secretions within the stomach but will continue to
work if it is in the centre of a food bolus. Gastric secretions will continue to
diffuse polysaccharides and other food components. Some carbohydrates
have been shown to decrease the rate of gastric emptying. These are
carbohydrates that increase the viscosity of gastric contents and this in turn is
associated with certain non-starch polysaccharides affecting the glycaemic
and insulin responses as well as lowering plasma cholesterol levels. Nonstarch polysaccharides are polysaccharides associated with dietary fibre
(cellulose, hemicellulose, pectin and gums) and oligosaccharides such as
insulin (Schneeman 2007).
Complex carbohydrates are digested by microbial enzymes and therefore
have important physiological effects throughout the GI tract as they are not
metabolised until they reach the colon. These include their water-holding
capacity, increased viscosity within the small intestine, bile acid binding, bulk
properties and they are also used for microbial growth in the colon. Increased
viscosity within the small intestine has been shown to delay the absorption of
sugar. Certain polysaccharides have also shown that they can bind or adsorb
bile acids. These effects are associated with the ability of certain
polysaccharides to have an effect on glucose and insulin responses as well as
the lowering of plasma cholesterol concentrations (Schneeman 2007).
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As the chyme enters the small intestine, the presence of protein, fat and acid
stimulates pancreatic and bile secretions. Pancreatic amylase continues the
hydrolysis of starch. This process of metabolism enables the monosaccharide
end products to be absorbed by the intestinal villi. However, not all starch is
digested, some remains in the small intestine as ‘resistant starch’. The nondigestible carbohydrates remain intact and continue to the colon.
Residual intestinal material including the resistant starch and non-starch
polysaccharides enter the colon through the ileo-cecal valve. The fermentation
of these carbohydrates by colonic bacteria produces by-products such as
short-chain fatty acids and gases such as hydrogen, carbon and methane.
Acetate, propionate, and butyrate are the main short chain fatty acids
produced. Colonocytes use butyrate as an energy source, acetate is used by
peripheral tissue and muscle cells while propionate is emptied from the portal
blood by the liver. The non-digestible carbohydrates have another important
role and that is in the elimination of faecal material. They do so both directly
by increasing stool mass and indirectly by increasing microbial mass through
supporting its growth. The major components of faecal material are water,
microbial mass and unabsorbed/undigested food (Schneeman 2007).
Carbohydrates historically were only considered to be required as an energy
source, however, carbohydrate binding proteins (lectins) are found on all cellsurface membranes (Osborn 2003). As well as bonding to proteins,
carbohydrates also bond to lipids and play an important role in signalling
processes on a cellular level (Boysen 2013).
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Chapter 3
3 Oesophageal and Gastric Cancer
3.1

Squamous cell carcinoma and Adenocarcinoma

The incidence of oesophageal and gastric cancer is increasing. This is
particularly evident with adenocarcinoma of the oesophagus (Griffin and
Raimes 2007). In the West, there has been a marked increase in
adenocarcinoma of the lower oesophagus and oesophagastric junction over
the last 20-30 years (Reynolds et al 2010). In particular, Ireland has one of the
highest rates of oesophageal cancer in Europe, with approximately 400 new
diagnosis each year (Reynolds 2010b).
Oesophageal cancer is three to four times more prevalent in men than women
(Fessler and Havrila 2012). Squamous cell carcinoma is usually located in the
upper or middle third of the oesophageal body (Surgical Tutor 2014). These
tumours are usually in the advanced stage upon detection and approximately
three quarters of these tumours will have extended into the muscularis and
lymph nodes (Griffin and Raimes 2007). For example, of 100 patients with
oesophageal cancer, approximately 50 of these patients will have localised
disease that can be treated with curative intent. A small minority of this group
may not be treated aggressively because of medical co-morbidities. The five
year survival rate is between 35-50 per cent in those patients treated with
curative intent (Reynolds 2010b). The overall oesophageal cancer survival
rate at five years is 22%. This includes all treatment (including curative)
intents and all stages of oesophageal cancer (Ten year cancer audit report
2012).
Adenocarcinoma of the oesophagus can arise from Barrett’s oesophagus.
This can occur when the normal squamous epithelial cells are exposed to
11

frequent or long durations of gastric acid exposure. The resulting metaplasia
causes the normal squamous cells of the distal oesophageal body to replicate
columnar cells, similar to those that line the stomach (Griffin and Raimes
2007). Adenocarcinoma of the oesophagus is usually located in the lower third
of the oesophagus.
The risk of developing adenocarcinoma of the oesophagus as a result of
Barrett’s oesophagus is suggested to be 30 times greater when compared to
the general population. For example, approximately 10% of patients with
gastro-oesophageal reflux disease will develop Barrett’s oesophagus. Of
these Barrett’s patients, about 1% will progress to develop carcinoma.
(Surgical Tutor 2014). Of the patients treated in St. James’s Hospital for
oesophageal

cancer,

66%

of

these

cancers

were

adenocarcinoma

morphology (Ten year cancer audit report 2012).
If high grade Barrett’s oesophagus or very early oesophageal cancer is
detected, then endoscopic mucosal resection and possibly radiofrequency
ablation therapy may be performed instead of surgery (Cancer Research UK
2014). Careful patient selection using endoscopic management appears to
reduce morbidity and mortality rates when compared to performing an
oesophagectomy. However, the long-term effectiveness of endoscopic
therapy needs further evaluation (O’Farrell et al 2013).
Obesity is thought to play a role in the development of cancer (Donohoe et al
2014). Rates of obesity are increasing rapidly. This is reflected with 65% of
men and 56% of women being overweight or obese in the United Kingdom.
Adipose tissue is primarily deposited either subcutaneously or centrally
(visceral fat). Visceral fat is thought to be more metabolically active and
secrets adipokines and cytokines which contributes to systemic inflammation
in addition to the expanded adipose tissue infiltrated with macrophages and
activated T-cells. According to the World Cancer Research Fund, it is
estimated that up to 35% of oesophageal cancers are attributable to obesity
(World Cancer Research Fund 2007). Data on the correlation between gastric
adenocarcinoma and obesity is limited (Donohoe et al 2014).
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Symptoms associated with oesophageal cancer include; dysphagia, weight
loss, hiccups, odynophagia, and a long history of reflux disease (Walsh et al
2011). Unfortunately dysphagia is rarely a symptom of early disease. Aims to
reduce mortality from oesophageal cancer include targeting factors such as
smoking, obesity, diet and reflux disease, early diagnosis and better cure
rates (Reynolds 2010b).

Advances in the surgical and

multimodal

management of patients who present with oesophageal cancer may improve
cure rates and survivorship (Croghan et al 2015).
Adenocarcinoma of the stomach occurs in the gastric mucosa and accounts
for approximately 90% of all malignant gastric tumours. Early gastric cancer is
defined as a malignant tumour that is limited to the mucosa or submucosa.
They are predominantly found within the lower two-thirds of the stomach. The
detection of early gastric cancer can lead to a very good prognosis. (Griffin
and Raimes 2007).
The most commonly found factors attributing to the development of gastric
cancer include mucosa inflammation, intestinal metaplasia of the gastric
mucosa, polyps, chronic peptic ulcer, gastric epithelial dysplasia and more
recently Helicobacter pylori has been linked with development of gastric
cancer (Griffin and Raimes 2007).
Following a distal gastrectomy for peptic ulcer disease, there is a higher risk of
developing cancer. The majority of tumours are found at or near the stoma
site. The gastric remnant may be associated with histological changes such
as gastritis, polyps and atrophy. There is a two–fold risk of developing cancer
when compared to a control group (Griffin and Raimes 2007).
About three quarters of gastrointestinal stromal tumours (GIST) are benign.
They are thought be composed of spindle cells with extracellular collagen.
They are more common in women and there are often multiple tumours
present (Griffin and Raimes 2007).
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The overall survival rate at five years for gastric cancer is 23%.This includes
all treatment (including curative) intents and all stages of gastric cancer. The
five year survival rate in those patients treated with curative intent is 46%
according to data published by St. James’s Hospital, Dublin (Ten year cancer
audit report 2012).
Pre-operative staging is generally carried out to evaluate the extent of the
malignancy and to determine if there is any metastatic disease. The cancer
cells can spread through tissue, the blood, and the lymphatic system. The
investigations that may be carried out help determine the stage of the disease
include; endoscopic ultrasound, computerised axial tomography (CAT) scan,
positron emission tomography (PET) scan.
St. James’s Hospital (National Centre for Oesophageal and Gastric Cancer
and the National Centre for Management of Early Upper Gastrointestinal
Mucosal Neoplasia), Dublin published a ten year cancer audit report in 2012
outlining trends and referral patterns, measuring and monitoring of quality and
care, complexity of treatment, as well as high quality data collection and
statistical analysis. In relation to oesophageal and stomach cancer, there has
been approximately 100% increase in new referrals over this 10 year period
e.g. in 2003 there was 118 patients treated for oesophagogastric cancer
increasing to 263 patients in 2012. Of this group, 41% of oesophageal and
35% of gastric cancer patients had a family history of cancer. In 2012, 82
complex major upper gastrointestinal resections were performed, 50 for
oesophagectomy and 32 for total gastrectomy (Ten year cancer audit report
2012).
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3.2 Radiotherapy and Chemotherapy

The management of oesophageal and gastric cancer may involve treatment
with chemotherapy and radiotherapy. They may be given alone, combined,
pre-surgery, post-surgery, or both.
Oesophageal cancer is a systemic disease in a vast majority of patients, it
requires

systemic

treatment.

Patients

treated

with

pre-operative

chemotherapy alone, may have their disease down-staged but surgery is
required for curative intent. If however, patients have pre-operative chemoradiotherapy, up to two thirds (depending on stage) will have a complete
pathological response. According to data from Connolly Hospital, Dublin, onethird of patients undergoing chemo-radiotherapy have a complete pathological
response to their treatment (Walsh et al 2011).
Radiotherapy administered pre-operatively (Neo-adjuvant) is given with the
view of reducing the tumour size and reducing the risk of iatrogenic
dissemination of tumour cells. Post-operative radiotherapy is performed to
eradicate disease at the resection or any suspected residual cancer cells. The
disadvantage of post-operative radiotherapy is that the newly reconstructed GI
segment may be subject to the full radiation dose which may compromise its
function.
Pre-operative chemotherapy is reported to induce early tumour regression
and reduce the incidence of drug-resistant tumour cells. The use of
chemotherapy post-surgery is often suggested in patients who are at a high
risk of recurrence. It is also believed that adjuvant therapy should begin
immediately after surgery because of the increased risk of metastases that
occurs following the resection of the primary tumour (Griffin and Raimes 2007)
An example of the regime of Radiotherapy and Chemotherapy given in St.
James’s Hospital is shown in Table 3-1.
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Table 3-1 - An Example of a Chemotherapy and Radiotherapy regime
Duration

Dose/Drug

Radiotherapy

25 sessions over 5
weeks. Mon-Fri over
the 5 week duration

41.4 Gy/23 Fractions

Chemotherapy

2 cycles starting on
days 1 and 22

Cisplatin80mg/m2 diluted in 1000ml
NaCl 0.9%. Infused over 2-6 hrs.
given day 1

Mannitol 10% 500ml. Infused
concurrently with cisplatin over 2-6
hrs. given day 1

5-Fluorouracil 1000mg/m2 diluted in
1000ml NaCl 0.9%. infused over 24
hours. given days 1-4
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3.3

Oesophagectomy and Gastrectomy

Not all oesophageal and gastric cancer patients will be suitable or benefit from
GI surgery. Preoperative assessment and staging of cancer is very important
in planning treatment options. Neoadjuvant therapy (chemotherapy and/or
radiotherapy) usually in combination with surgical resection of the tumour is
the most successful outcome for treating oesophageal and gastric
malignancies. For those patients that require palliative care, treatments such
as stenting may be used to try and alleviate symptoms of oesophageal and
gastric cancer (Griffin and Raimes 2007). The patient’s anatomy, age, fitness,
previous medical history and type/extent/location of the tumour all play
important roles in the surgeons approach to each individual case.
Resection of an oesophageal tumour is a very complicated and delicate
surgical procedure. It often involves the removal and reconstruction of part or
most of the oesophageal body and/or the oesophageal-gastric junction as well
as the removal of lymph nodes. This surgical procedure is called an
oesophagectomy. If the tumour has extended into the stomach, a partial
gastrectomy may also need to be performed (Cancer Research UK 2014).
Different types of oesophagectomies can be performed depending on the
location, type and extent of the malignancy. An oesophagectomy may involve
a total or partial resection of the oesophagus. The procedure is typically
named after the surgeon that developed them:
• Subtotal two stage Oesophagectomy (Ivor-Lewis). Right thoracotomy and
abdominal incision with intra-thoracic anastomosis (RCS 2014)
• Subtotal three-stage oesophagectomy (McKeown). Right thoracotomy and
abdominal incision with neck incision for anastomosis (RCS 2014)
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• Transhiatal Oesophagectomy. Abdominal incision with neck incision for
anastomosis
• Minimally invasive oesophagectomy (Thoracosopic +/- lapasroscopic
oesophagectomy)
The thoracic incision is made to mobilise the oesophagus while the abdominal
incision is performed to prepare the stomach. Reconstruction involves
creating a new oesophageal tube by performing an anastomosis to join the
stomach to the healthy oesophageal remnant. The anastomosis can be
performed via a cervical incision. In those patients with tumours in the lower
third of the oesophageal body, a partial oesophagectomy may be performed.
This can be carried out transhiatally using only an abdominal incision (NICE
2011).
Surgeons differ in their technique when performing an oesophagectomy and
can approach the tumour via the neck, chest or abdomen. Reconstruction of
the oesophagus using the stomach as a substitute is the preferred option as it
involves only one anastomosis, refer to Figure 3-1 to Figure 3-3 (Griffin and
Raimes 2007). However, a part of the small intestine or a colonic transposition
can be performed depending on the circumstances, Figure 3-4.
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Figure 3-1 - Oesophagectomy with stomach anastomosis
(Cancer Research UK 2014)

Figure 3-2 - Oesophagectomy with a partial gastrectomy
(Cancer Research UK 2014)
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Figure 3-3 - Total oesophagectomy
(Cancer Research UK 2014)

Figure 3-4 - Oesophagectomy with colonic transposition
(Cancer Research UK 2014)
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A gastrectomy is a surgical operation involving the removal of the stomach. It
may involve the removal of the entire stomach (total gastrectomy) or part of
the stomach (partial gastrectomy).
A partial gastrectomy can involve the removal of the proximal stomach or it
can be a distal gastric resection. A distal gastrectomy may involve the removal
of the antrum, distal two-thirds of the stomach or distal four-fifths of the
stomach. A total gastrectomy involves the complete removal of the stomach,
gastroesophageal junction and pylorus. Other types of gastrectomy include a
wedge resection, sleeve resection, and pylorus-preserving segmental
gastrectomy. Laparoscopic partial gastric resections can also be performed.
This approach takes more operating time but is thought to be associated with
a faster GI recovery time (Wirtzfeld 2014). A lymphadenectomy is usually
performed in conjunction with the gastric resection. As mentioned above, each
case is tailored by the surgeon depending on the position of the cancer and
the margins necessary to ensure complete removal of malignant cells.
One of the most important aims when performing a curative gastrectomy is to
ensure complete resection of the malignancy. It has been suggested that
resection margins around the tumour should be >2-3cm for early gastric
cancer and >2-6cm for advanced gastric cancer (Wirtzfeld 2014).
The most common reconstructions following a partial gastric resection include
the Billroth I, Billroth II, and Roux-en-Y. Billroth I (refer to Figure 3-5)
preserves duodenal and jejunal connection by anastomosing the remnant
stomach to the duodenal stump.

The most common complication of this

technique is the reflux of biliary contents into the stomach causing alkaline
gastritis (Wirtzfeld 2014).
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Billroth II preserves the jejunal but not the duodenal connectivity by
anastomosing the remnant stomach to the proximal jejunum. It is performed
when Billroth I is not feasible. In addition to alkaline gastritis, patients may
also

experience

malabsorption

because

the

duodenal

segment

is

compromised (Wirtzfeld 2014). As can be seen in Figure 3-6, the pancreatic
and bile juices do not meet the stomach contents entering the small intestine
until they flow down into the jejunum.
Roux-en-Y (refer to Figure 3-7) involves the diversion of biliary drainage away
from the gastric remnant. Patients may experience less reflux than if the
techniques above were used, but dumping syndrome and gastric atony may
be an issue in some (Wirtzfeld 2014). It is usually performed for a total
gastrectomy.
Alkaline reflux can be a complication following a gastrectomy, especially if the
pyloric and/or lower oesophageal sphincter is resected. The incidence of
developing reflux oesophagitis depends on the type of reconstructive surgery.
The Roux-en-Y technique is associated with a lower rate of reflux
oesophagitis. Factors that affect the incidence of developing alkaline reflux
oesophagitis include; the length of the jejunal loop and the site where
pancreatic and bile secretions enter the intestines. It is suggested that the
jejunal loop should be 35-40cm but ideally over 50cm in length (Matei et al
2010).
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Figure 3-5 - Billroth I reconstruction for gastric carcinoma
(GSI 2014)
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Figure 3-6 - Billroth II reconstruction for gastric carcinoma
(GSI 2014)
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Figure 3-7 - Roux-en-Y reconstruction for gastric carcinoma
(GSI 2014)
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Any gastric resection may result in major nutritional consequences for the
patient and impact their recovery and quality of life post-surgery (see section
3.4). Therefore the aims of reconstruction for a gastrectomy is to perform the
least complex anastomosis to allow adequate nutritional intake. In addition to
this, alteration in GI physiology should be kept to a minimum, reflux of
intestinal secretions into the oesophagus should be prevented, and the
reconstruction should not be prone to long-term complications such as SIBO
(Griffin and Raimes 2007).
As with any surgical procedure, complications can occur. These may include
general complications or those specific to the oesophageal or gastric
resection and reconstruction. Such complications include: haemorrhage,
anastomotic leak, intra-abdominal sepsis. Long term complications include:
early satiety, dumping syndrome, SIBO, bile reflux and general malnutrition
and weight loss (Griffin and Raimes 2007).
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3.4 Nutritional consequences of upper GI surgery

Surgical resection of the oesophagus or stomach for cancer may produce
varied forms of malabsorption since the GI tract is our major source of
nutrients (Lawrence 1977). Malnutrition following an oesophagectomy is
common. This surgical procedure results in an altered stomach anatomy – the
stomach is now smaller and in a different position. As a result of this, dumping
syndrome due to rapid emptying of food into the duodenum can occur. In
contrast, some patients may experience delayed gastric emptying because
the vagus nerve is cut during surgery (Fessler and Havrila 2012).
Impaired nutrition is more commonly observed after a partial or total
gastrectomy when compared to oesophagectomy patients (Lawrence 1977).
The stomach plays many important roles in digestion, for example it acts as a
reservoir, mixes and grinds food, destroys ingested bacteria, secretes
digestive juices and controls the emptying of gastric contents into the
duodenum (DLGIP 2009). Therefore, it is not surprising that surgical
manipulation and resection of all or part of the stomach has a major effect on
nutritional status.
The stomach is a complex organ and has many important functions. This
includes its ability to accommodate by dilating in response to a meal without
any significant rise in intragastric pressure. Another important function is the
controlled release of food from the stomach into the small intestine. This
allows the chyme to be mixed with pancreatic, bile and intestinal secretions at
a rate which allows optimal digestion and absorption. An intact and nerve
stimulated pyloric sphincter is vital to maintain this gastric emptying function.
Therefore any gastric resection may result in significant malnutrition for the
patient (Griffin and Raimes 2007).
Following a gastrectomy, the impairment of fat absorption plays an important
role in malabsorption. Impaired absorption of vitamins (e.g. vitamin B12) and
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iron may also occur. The stores of Vitamin B12 are slowly depleted after a
total gastrectomy but the development of megaloblastic anaemia has a
delayed onset (6 months to 4 years for onset to appear) because the liver has
a large store of this vitamin which delays the clinical appearance of B12
deficiency.
Dumping syndrome is a common complaint and one reason is thought to be
due to the loss of pyloric function. Symptoms of dumping syndrome include
epigastric fullness, hyperperistalsis, nausea, vomiting or diarrhoea.

Other

non-abdominal symptoms can also occur as early as 15 minutes after
ingestion of food such as tachycardia, sweating, weakness and measurable
alterations in cardia output and regional blood flow (Ukleja 2006). Dumping
syndrome can be divided into two types; early and late. Early dumping
syndrome occurs soon after the ingestion of a meal. It occurs because of the
rapid emptying of the stomach contents into the intestine. Late dumping
occurs about one or more hours after ingestion of a meal. It is caused by
excess insulin secretion in response to the stomach’s rapid emptying into the
small intestine, refer to Figure 3-8. (RCS 2014).
It has been suggested by experimental investigations, that these symptoms
occur as a result of a large volume shift into the bowel following a
hyperosmolar meal. The large shift of fluid into the intestine is associated with
a loss of water from the plasma, and can appear as alteration in cardiac
output and redistribution in blood flow, which in turn affects the renal blood
flow, the digital blood flow and intestinal blood flow (Lawrence 1977). The
rapid entry of food into the intestine can stimulate the pancreas to release
insulin causing hypoglycaemia. The inappropriate release of vasoactive GI
hormones causes peripheral and splanchnic vasodilatation and vasomotor
symptoms such as tachycardia and dizziness (Ukleja 2006).
Low carbohydrate diets (especially simple carbohydrates) are necessary to
reduce symptoms while increasing the intake of fibre to slow motility and
reduce insulin peaks. Late dumping syndrome which is a consequence of
reactive hypoglycaemia occurs 1-3 hours after a meal and approximately 25%
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of patients with dumping syndrome will experience this late phase of
symptoms. These symptoms include difficulty with concentration, hunger,
decreased consciousness, perspiration and tremor (Ukleja 2006).

Figure 3-8 - Pathophysiology of Dumping Syndrome
(Kanth 2014)
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Chapter 4
4 Bacterial overgrowth of the small intestine
4.1 Pathophysiology of Small Intestinal Bacterial Overgrowth

Small intestinal bacterial overgrowth is usually defined as the presence of
>105 colony forming units (CFU)/mL of bacteria in the proximal small intestine.
It has been suggested however, that a lower colony count (e.g. >10 3 cfu/mL)
may be enough to cause symptoms in an individual (DiBaise 2008). In SIBO,
the bacterial species in the small intestine closely resembles the 300-400
species normally present in the colonic region (Zaidel and Lin 2003).
In healthy individuals, it is normal for small numbers of bacteria to be present
in the stomach and small intestine. These bacteria are usually gram positive
aerobes, anaerobes are rare. Colonic anaerobes (primarily fastidious
anaerobes e.g. Bacteroides, anaerobic lactobacilli, and clostridia) are not
normally found in the proximal small intestine, which contrasts with the mostly
aerobic bacteria in this portion of the intestine (Zaidel and Lin 2003).
Lactobacilli are less gas producing than some other bacteria such as Clostrida
(Kumar et al 2010).
In the distal part of the small intestine, the bacteria more commonly resemble
that of the colon. These are mostly gram negative aerobes but with a minor
contribution from anaerobes present (Table 4-1). This region is separated by
the ileo-cecal valve, which acts like a barrier. At the ileocecal valve, the
intestinal transit of luminal contents is slowed, allowing some colonic bacteria
to move into the terminal ileum (Shelly 2009). Distal to this valve, the bacteria
increase in number and consist mainly of anaerobes, refer to Figure 4-1
(Simren and Stotzer 2006). Bacteria that reside in the proximal colon grow at
a fast rate because they have a plentiful supply of dietary nutrients. This
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results in a decrease in pH because of the vast short chain fatty acid
production. In the distal colon, bacteria are more slow growing as substrate
availability is lower and the pH is more neutral (Gibson and Roberfroid 1995).
Table 4-1 - Concentration of bacteria CFU/mL (Simren and Stotzer 2006)

Aerobes

Stomach Jejunum Ileum

Caecum

102-103

102-109

Anaerobes
Total Count

102-104

0 103-107

0
102-103

105-108

102-104
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105-108

109-1012
1010-1012

Figure 4-1 - Normal intestinal bacterial flora
(Vanderhoof & Pauley-Hunter 2013b)

* Bacteria are not listed in quantitative order
It must be considered that the total growth rate may consist of an overgrowth
of gram positive bacteria. This is mainly due to upper respiratory flora and
this is a common finding in the small intestine of healthy elderly people. It is
thought that this type of gram positive bacteria is not associated with
symptoms of SIBO. In contrast, the gram negative, anaerobes and enterocci
bacteria correlate with such symptoms. They also deconjugate bile acids (as
discussed in more detail in Section 4.3 ‘Consequences of SIBO’), affect the
binding capacity of intrinsic factor, and reduce the absorptive function of
enterocytes (Simren and Stotzer 2006).
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It is thought that each individual person has their own distinctive composition
of colonic bacteria which appears to be affected by dietary patterns, intake of
various nutrients and geographical region. However, it is also suggested that
even in those patients with the same diet, the effects of ingested food on
individual microflora composition may be very different (Mai and Morris 2014).
The ‘Gold Standard’ diagnosis of SIBO is believed to be through the culturing
of jejunal aspirate. This can be defined as being positive for SIBO if the total
growth is >104 bacteria and/or there is growth of gram negatives or anaerobes
(Simren and Stotzer 2006). This however, is not an ideal method of diagnosis
since the intestinal bacterial flora may be present in the more distal segment
of the small intestine (DiBaise 2008). Technically, direct culture is limited to
detecting SIBO in the upper 60cm of the small intestine (Nucera et al
2005).This is further emphasised by the high rate of false negative results and
the low reproducibility rates (Zaidel and Lin 2003). In addition to this, it is a
costly and invasive method, many bacterial species do not grow in routine
culture media, contamination of the endoscope and catheter can occur as it
passes through the GI tract, and proper handling of the sample is required
(Dukowicz et al 2007). Culturing of small intestinal aspirates can however,
increase the detection rate of SIBO by 12% (Rusu et al 2012). Another study
by Teo M. et al concludes from their findings that duodenal fluid aspiration and
culture is the most accurate method of testing for SIBO with high specificity
when compared to hydrogen breath testing. This study however, used a
different methodology for their HBT findings (Teo et al 2004).
There are numerous factors and ‘defence’ mechanisms involved to prevent
SIBO, and control the bacterial population in the small intestine. The two
major features include; gastric acid secretion which inactivates and destroys
many organisms before they enter the proximal segment of the small intestine
and, normal intestinal motility (especially Migrating Motor Complexes) which
prevents stagnant activity to prohibit the attachment of ingested organisms
within the intestinal lumen. Other factors include; immunoglobulins which
provides adequate mucosal immunity, the ileocecal valve, and the secretion of
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digestive enzymes by the pancreatic and billiary systems (DiBaise 2008; Syed
2014).
Migrating Motor Complexes (MMC’S) usually occur between meals, i.e. they
are interdigestive. For obvious reasons, MMC’s more often occur at night.
They result from migrating electrical complexes which cause regular pressure
changes within the wall of the stomach and small intestine.
The Myenteric plexus generate the MMC’s, however, many hormones
including motilin also play an important role in MMC initiation and propagation.
MMC’s are replaced by peristalsis and segmenting waves during a meal but
may persist if a meal is light. They can start anywhere in the small intestine
and travel distally down the GI tract.
Their role is important in preventing SIBO by mechanically moving debris and
bacteria distally, and lubricating the stomach and small intestine. This is
particular to phase III of the MMC cycle which comprises of an uninterrupted
band of regular contractions which occurs in the small intestine at a rate of 1012 min. These are forceful contractions which move the intestinal contents
distally. This phase lasts between 2-12 minutes and occurs every 90-120
minutes between meals (DLGIP 2009).
A very early study by Vantrappen et al (1977) suggested that disorders of the
interdigestive motor complex may be an important factor in the pathogenesis
of bacterial colonisation in the small intestine (Vantrappen et al 1977). Another
study by Stotzeer and associates, demonstrated that patients with SIBO lack
interdigestive phase III activity in the small intestine and gastric antrum but
have a higher motility index in the distal part of the duodenum. This may be a
compensatory increase in motility in the distal intestine (Stotzeer et al 1996).
Motility dysfunction post GI surgery is a common complication due to
autonomic nervous dysfunction and GI hormone disruptions leading to a
disruption in the MMC activity (Mochiki et al 2007).
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GI Surgery that alters and affects the anatomy of the small intestine has
commonly been associated with SIBO (Zaidel and Lin 2003). Other conditions
related to the development of SIBO include:
Stasis (Anatomic):
• Small Bowel Diverticula
• Surgical e.g. resections, ileal bypass, surgically created blind loops
• Intestinal strictures
• Crohn’s disease
• Radiation
• Fistulae (Zaidel and Lin 2003; Vanderhoof and Pauley-Hunter 2013b)
Functional Factors
• Intestinal dysmotility syndromes e.g. MMC dysfunction
• Achlorhydria
• Autonomic neuropathy
• Reduction of gut associated lymphoid tissue (DiBaise 2008)
Miscellaneous
• Cirrhosis
• Acid supressing medications, e.g. proton pump inihibitors, H2 receptor
antagonists
• Pancreatitis
• Immune deficiency
• Antimotility medications
• Radiation enteritis
• Diabetes mellitus
35

• Short bowel syndrome
• Advanced age (DiBaise 2008; Zaidel and Lin 2003)
Patients with Diabetes Mellitus (DM) may suffer from impaired gastrointestinal
motility and/or gastroparesis. Therefore, DM may be a condition associated
with the development of SIBO. This is because poorly controlled and longstanding diabetes can injure the enteric nervous system leading to impaired
GI motility (Dukowicz et al 2007).
Medications such as antidepressants and opiates can disturb the motility in
the intestine because of their effect on muscles and nerves (Right Diagnosis
2014). Other medications that affect the motility in the GI tract include
anticholinergic agents, adsorbents and absorbents. The mechanism of action
of the antimotility agents is to reduce and slow the motility and peristalsis in
the small and large intestine (CueFLASH 2014).
Small intestinal bacterial overgrowth is more common in the elderly population
because of the onset of new diseases (e.g. diabetes), dietary changes,
decreased immune function and reduction in gastric acid, and decreased
intestinal motility. This may be caused by the consumption of a large number
of medications that contribute to hypomotility (Syed 2014; Dukowicz et al
2007). A number of studies have compared the prevalence of SIBO in older
adults compared with control groups. Parlesak et al showed that SIBO tends
to be more prevalent (15.6%) in older patients (61-94 years of age) than in
healthy controls (5.9%, 24-59 years of age); however there was variability in
their methodology of testing (Parlesak et al 2003). Teo M. et al (2004)
reported that SIBO was identified in 48% of patients in a prospective study
looking as the possible cause of chronic diarrhoea (Teo et al 2004).
Abnormal laboratory findings are usually only seen in patients with complex or
severe SIBO. There may also be evidence of macrocytic anaemia due to
malabsorption of vitamin B12 and the presence of faecal fat. These laboratory
findings may include a decrease in thiamine and nicotinamide levels as well
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as an increase in serum folate and vitamin K levels (Vanderhoof and PauleyHunter 2013b). These findings are not diagnostic features of SIBO but are
supportive of the diagnosis.
Similarly, endoscopic findings are usually normal in patients with SIBO,
however in severe cases where colitis and ileitis occurs; inflammation may be
seen during endoscopic examination (Vanderhoof and Pauley-Hunter 2013b).
If diarrhoea is present, stool testing may be performed to see if the cause of
the diarrhoea is due to fat malabsorption, inflammation/infection or an osmotic
or secretary cause. If faecal fat is present in the stool, fat malabsorption which
may result from SIBO, celiac disease or fat maldigestion (e.g. pancreatic
insufficiency, chronic pancreatitis) is indicated (Vanderhoof and Pauley-Hunter
2013b). An osmotic gap can be calculated by measuring stool electrolytes and
osmolarity. A gap of >50 mosm indicates osmotic diarrhoea which is
associated with the ingestion of a poorly absorbed substrate such as fructose.
A small osmotic gap and a stool weight of > 1kg/day (volume>1 L/day)
indicates secretory diarrhoea (Fan and Sellin 2009).

37

4.2 Benefits of colonic bacteria

Intestinal microflora provides an important role in metabolic and protective
functions for the host. In terms of protective function, for example, the
microbes assist in preventing pathogens potentially invading the intestinal
mucosa by inhibiting attachment and subsequent entry of such pathogens into
epithelial cells. Important metabolic functions include the fermentation of
nondigestible carbohydrates such as starches, cellulose and pectins (large
polysaccharides) and some oligosaccharides that avoided digestion, all of
which provide energy to the colon (Canny and McCormick 2008).
Colonic microbiotas perform numerous functions that benefit the digestive
process. These functions include; the production of micronutrients, the
metabolism and/or activation of medications, and the biotransformation of bile
salts. These microbiota are also involved in the fermentation of indigestible
polysacchairdes, and the prevention of luminal colonization by pathogenic
microorganisms as mentioned above (DiBaise 2008).
Evidence suggests that fibre degradation occurs in the colon. As there are no
fibre enzymes, fibre enters the caecum in its unchanged state. The colonic
bacteria ferment the fibre to short chain fatty acids, the most important of
these are acetate, propionate and butyrate. The major source of energy for
colonic epithelium (colonocyte) comes from butyrate (Chapman 2001).
Bifidobacteria

(major

group

of

saccharolytic

bacteria),

makes

up

approximately 25% of the total bacterial population. It has many health
benefits including, lowering blood cholesterol levels, reducing blood ammonia
levels, producing vitamins such as B vitamins, folic acid and digestive
enzymes such as casein, and lysozyme. It inhibits the growth of potential
pathogens and promotes immune function against malignant cells (Gibson
and Roberfroid 1995).
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Intestinal bacteria also play a role in the enterohepatic circulation by
producing enzymes which deconjugate bile acids in the colon allowing some
reabsorption of bile across the intestinal wall (Sherwood 1996). Most however
are eliminated in the faeces.
Colonic bacteria can cause both beneficial and harmful effects to the host.
Normal flora balance discourages infection by exogenous pathogens and
overgrowth of pathogenic organisms by the production of antimicrobial
substances or short chain fatty acids by resident flora, which inhibits the
growth of these pathogens. Therefore antibiotics that reduce the intestinal
flora can disrupt this balance and may result in infections or pathologic
overgrowth (Sherwood 1996).
Microflora in the colon also aids in the excretion process of various toxic
substances and the flora has also been shown to stimulate immune function
through Peyer’s patches and gut-associated lymphoid tissue. Disturbances in
immune function can be associated with intestinal diseases such as Ulcerative
colitis and Crohn’s disease (Mai and Morris 2004).
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4.3 Consequences of Small Intestinal Bacterial Overgrowth

One of the major effects of SIBO is the undesirable inflammatory epithelial
changes that may result in the dampening of villi, damage to the brush border,
and the altered cytokines/mediators which affects the absorption process
(DiBaise 2008). Normally, in the colon, the epithelial cells and microflora form
a barrier that protects the intestine from pathogen invasion. Impairment of this
barrier may result in inflammatory disease see Figure 4-2 (Canny and
McCormick 2008).

Figure 4-2 - Epithelial Barrier
(Canny and McCormick 2008)
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Malabsorption of fats is another consequence of SIBO, this occurs because of
bile acid deconjugation by intraluminal bacteria which – in turn, affects micelle
formation. A significant concentration of conjugated bile acid is required for
the formation of these micelles which transport the fat molecules across the
intestinal lumen. Therefore, SIBO indirectly damages the absorptive mucosa
and can lead to chronic diarrhoea which is secondary to poor fat digestion and
absorption (Zaidel and Lin 2003). Chronic diarrhoea is defined as greater
than 3 stools a day for at least four weeks (Teo et al 2004). Protein and
carbohydrate malabsorption as well as fat malabsorption may also be
impaired as a result of bile acid deconjugation. This is as a result of
substances such as lithocholic acid being produced which exerts a toxic effect
on the intestinal epithelium (DiBaise 2008).
Anaerobic bacterial utilization of Vitamin B12 within the intestinal lumen may
result in a deficiency in this vitamin and lead to megaloblastic anaemia.
Subsequently the bacterial synthesis may lead to an elevation in folate levels
(DiBaise 2008). Other vitamin deficiencies may also arise as a consequence
of SIBO and impaired micelle formation and includes deficiencies in fatsoluble vitamins such as vitamin A (e.g. night blindness), D (osteomalacia,
tetany), E and K (prolonged prothrombin times) this however is a rare
occurrence (Dukowicz et al 2007).
Most importantly, SIBO can very often affect the patient symptomatically. This
can be both quite uncomfortable for the patient and can affect their lifestyle
and/or quality of life. Symptoms are produced as a result of by-products
released by the bacteria when they compete with the natural digestive
process and metabolise, particularly carbohydrates, within the lumen of the
small intestine. Gases such as Hydrogen, Methane and Carbon Dioxide and
short-chain fatty acids are produced. These gases can move in both an
antegrade and retrograde direction through the GI tract and cause nonspecific GI symptoms such as nausea, abdominal/epigastric discomfort,
flatulence and abdominal distension. A large amount of CO2 remains in the
small intestine and leads to bloating. In fact, these symptoms can often mimic
Irritable Bowel Syndrome (IBS). Malabsorption of fat and poor fat digestion
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can lead to steatorrhoea and fat soluble vitamin deficiencies. Diarrhoea can
also result from the short-chain fatty acid by-products. This is because they
exert an osmotic effect and absorb water into the intestinal lumen
(Ledochowski M and Ledochowski E 2008). Some patients with SIBO
however may be asymptomatic (Vanderhoof and Pauley-Hunter 2013a).
In addition, the type of bacteria present plays a role in the manifestations of
signs and symptoms of SIBO. For example, a predominance of microbial flora
that deconjugate bile acid

may lead to fat malabsorption or bile acid

diarrhoea, while bacteria that prefer to metabolise carbohydrates to short
chain fatty acids and gas may cause bloating (Dukowicz et al 2007).
Methane slows down gut transit and may cause constipation (less than 3
stools per week). In contrast, it has been shown that excess hydrogen
production is linked to chronic non-specific diarrhoea and higher stool
frequency (Kumar et al 2010). A study by Kumar S. et al showed that the
production of methane seems to be much more common in control groups
than in patients with IBS. This might explain the bloating symptom which is so
frequent amongst IBS suffers since 4 atoms of hydrogen combine to produce
1 molecule of methane (Kumar et al 2010).
Another complication of SIBO which has been demonstrated in rats is
bacterial translocation. This is where the bacteria move from the intestinal
lumen across the mucosal barrier which can lead to the appearance of the
bacteria in the mesenteric lymph nodes and visceral organs. This may lead to
the complication of immune response activation and could be related to
immune mediated disorders such as fibromyalgia, interstitial cystitis, and
chronic fatigue syndrome (Petrone et al 2011).
D-lactic acidosis can occur due to bacterial overgrowth metabolising
carbohydrates leading to excess production of D-lactic acid.

The clinical

presentation is characterised by recurrent episodes of unusual neurological
manifestations and severe metabolic acidosis (Zhang et al 2003). Common
features include slurred speech, memory loss and confusion especially after
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high carbohydrate meals (Emmett 2013). In severe cases, colitis and ileitis
can occur which may be evident on endoscopy. This inflammation can mimic
a flare of Crohn’s Disease (Vanderhoof and Pauley-Hunter 2013a).
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4.4 Small Intestinal Bacterial Overgrowth Following Surgery

After surgery, the presence of adhesions may play a role in intestinal stasis
and contribute to SIBO (Petrone et al 2011). A study by Petrone P. et al
showed that in a group of 57 patients who were tested for SIBO, 45 patients
had a positive result. Of these 45 patients, 82% had a history of abdominal
surgery. They also found in their study that the mean age of SIBO patients
was higher than that of SIBO-negative patients (57 vs 44 years). The surgery
performed on this patient group was both laparoscopic and open surgery. The
most frequent surgery was on the female reproductive organs (64%) followed
by the hindgut, foregut and midgut (Petrone et al 2011).
Small intestinal bacterial overgrowth following a gastrectomy is quite common
because of complex reconstructions and pouches. One of the reported
reasons is due to the loss of gastric acid, while another reason is the
formation of blind-loops (Griffin and Raimes 2007). Impaired intestinal motility,
reduction in gastric acid and disrupted immunologic secretions are also
thought to contribute to the development of SIBO. Steatorrhoea and
megablastic anaemia are the most common clinical features. It is estimated
that dumping syndrome can occur in 15-50% of patients following
oesophageal and gastric surgery.
Paik et al examined a total of 77 patients for bacterial overgrowth postgastrectomy using a hydrogen-methane glucose breath test and they also
performed simultaneous dumping syndrome questionnaires, serum glucose,
hematocrit and pulse rate measurements.

The prevalence of dumping

syndrome in this study was 46.1%. Following the ingestion of glucose,
samples were taken every 10 minutes up to 2 hours. A positive study was
interpreted as an increase in hydrogen or methane concentration of >12ppm
above baseline. Of those patients that were found to be positive (77.6%) for
SIBO, 73.7% had an increase of >12ppm by the 50 minute mark and all 59
patients (77.6%) by the 60th minute. At the 20 minutes interval post ingestion
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of glucose, the cumulative positivity appeared and reached plateau at 60
minutes.
Only 1 (1.7%) patient was positive for SIBO by methane measurement only.
This study also found no difference in positive and negative studies regarding
patient age, gender, time of testing post-surgery, type of gastric surgery, and
the presence of dumping syndrome. This was also the case for BMI and
laboratory data for nutritional status. It was noted in this paper that false
positive results due to rapid intestinal transit should be considered. However,
the study pointed out that even if the cut-off point for positivity was at the 30
minute increment, 52.6% of patients would still have tested positive for SIBO
(Paik et al 2011).
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4.5 Management of Small Intestinal Bacterial Overgrowth

Intestinal Stasis, when not associated with surgical conditions, should be
corrected where possible e.g. the elimination or substitution of certain drugs
known to decrease intestinal motility i.e. narcotics, benzodiazepines. In other
cases where intestinal motility may need to be increased, prokinetic agents
may help in this instance but it is not known how much of a benefit they have
in aiding the treatment of patients positive for SIBO. To induce Phase III of the
migrating motor complex (described in Section 2.1), Octreotide may be
prescribed (Vanderhoof and Pauley-Hunter 2013a). Post antibiotic therapy, a
low dose of erythromycin may be prescribed. This antibiotic has hormone
properties which stimulates small intestinal peristalsis (SIG 2014; Ohio GI
2014).
In the management of SIBO, nutritional intervention and support plays an
important role. For those with diagnosed or suspected SIBO, it is quite
common in clinical practice to prescribe an antibiotic regime to reduce the
bacterial overgrowth and reverse mucosal inflammation associated with SIBO
(Dukowicz et al 2007). This regime will be discussed in further detail in
Section 4.6.
Supplements to counteract micronutrient deficiencies may be required in
addition to short term diet restriction i.e. fat restriction to reduce steatorrhoea.
It may be necessary to have a diet that consists of nutrients which are readily
absorbed in the intestine, thereby leaving fewer calories for bacterial
metabolism (Vanderhoof and Pauley-Hunter 2013a).
As mentioned above, excessive or prolonged acid suppression may or may
not be a contributing factor. In those patients where proton pump inhibitors
(PPI’s) are suspected to be associated with the development of symptoms
caused by SIBO, a reduction in PPI and/or lifestyle changes to control gastric
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reflux may be recommended. However, the effects of PPI’s on HBT results
remain controversial (Dukowicz et al 2007).
In severe cases where other management strategies have failed, surgery may
be considered in those patients who have significant weight loss and
diarrhoea. This may include postoperative repair of strictures and blind loops,
intestinal tapering procedures and intestinal transplant. It may also include
surgical correction of strictures, fistulae and diverticula (Vanderhoof and
Pauley-Hunter 2013a; Syed 2014). The primary goal is to reduce the bacterial
overgrowth rather than total eradication of protective microorganisms with
antibiotics therapy (Syed 2014). Pharmacological components may be
prescribed in combination with the antibiotic therapy to improve and
enhance/restore small intestinal motility.
In cases where the underlying aetiology causing SIBO is unknown, additional
tests should be performed e.g. imaging of the small bowel to rule out
anatomical causes of SIBO such as intestinal dilations, diverticulitis, fistulae,
or strictures. In those with more than two episodes of SIBO with negative
imaging and endoscopies, magnetic resonance cholangiopancreatography
(MRCP) may be considered to rule out chronic pancreatitis (Vanderhoof and
Pauley-Hunter 2013b).
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4.6 Antibiotic Regime

Currently, St. James’s Hospital regimen for treatment of SIBO is rifaximin
400mg QDS for 7 days. This is given as first line antibiotic therapy to reduce
the bacterial flora levels within the small intestine.
Most patients respond well to appropriate antibiotic therapy (Shelly et al
2009). Because of the diverse nature of the organism, therapy providing
coverage for both aerobic and anaerobic organisms is recommended (DiBaise
2008). Examples include:
1)

Amoxicillin-clavulinic acid (30mg/kg/day)

2)

Metronidazole

(20mg/kg/day)

combined

with

a

cephalosporin

(30mg/kg/day).
3)

Norfloxacin (800mg/day)

4)

Rifaximin (1650mg/per day) (Vanderhoof and Pauley-Hunter 2013a).

The antibiotic rifaximin is poorly absorbed and has shown to be effective when
treating patients who were positive for SIBO using glucose substrate when
compared to Chlortetracycline [(70% vs 27% respectively) (DiBaise 2008)].
Rifaximin treats infections only in the intestine. It passes through the stomach
and into the intestine without being absorbed into the blood stream. Clinical
resistance tends to be less than with other antibiotics (Vanderhoof and
Pauley-Hunter 2013a). Another study by Vanderhoof (2013) reported in their
literature review that 69% of patients treated with rifaximin had a clinical
response compared with other non-rifaximin antibiotics (Vanderhoof and
Pauley-Hunter 2013a). In contrast, a randomised trial comparing rifaximin and
metronidazole recommended the benefits and use of metronidazole for
treating SIBO and associated symptoms (Dukowicz et al 2007).
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Nucrea et al suggested treating patients with a one week course of either
rifaximin, metronidazole or fluroquinolines. In their study of 64 patients who
were treated for SIBO, 40 (62%) showed normalization of their lactulose HBT
following antibiotic therapy (Nucera et al 2005).
The duration and dosing regimen of the antibiotic therapy for rifaximin varied
amongst studies and reports. Some suggest a one week course, some a 7-10
day course while others recommend a two week course of the antibiotic
(Nucera et al 2005; Petrone et al 2011; Vanderhoof and Pauley-Hunter
2013a; Dukowicz et al 2007). Variations in the dosage of rifaximin have also
been subject to controversy. Some institutions believe that 550mg bd is
sufficient to treat SIBO (Andreyev et al 2014). It has been suggested that
some patients may require prolonged therapy of one to two months before a
response is seen and symptoms improve. Patients with recurrent symptoms
may require continuous or cyclical antibiotic therapy i.e. first 5-10 days of
every month (Syed 2014). Recurrence is common after treatment and tends to
be in older adults with chronic PPI use (Vanderhoof and Pauley-Hunter
2013a; Lauritano et al 2008).
The use of probiotic therapy to treat SIBO has been the subject of diverse
opinions. Outcomes using probiotic therapy is inconclusive and not generally
recommended (Syed 2014).
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Chapter 5
5 Methodology
5.1 Method of physiological measurement
At rest and while appropriately fasting, humans do not exhale hydrogen, it is
generated as a result of anaerobic metabolism (Eisenmann et al 2008). When
Hydrogen is produced as a by-product of bacterial metabolism, it is readily
and quickly absorbed across the lumen of the intestine (Simren and Stotzer
2006). The gas enters the circulatory system and travels in the normal
systemic flow towards the respiratory system. Here, the hydrogen gas is
expired along with other gases through alveolar exchange. It is this expired
hydrogen gas that is measured using the HBT device (Gastro+ Operating
Manual 2014).
Both glucose and lactulose are the substrates most commonly used for
detecting SIBO. Lactulose is in some circumstances preferred as it travels the
length of the small intestine and therefore has the ability to detect SIBO in the
more distal parts of the small intestine. As a synthetic disaccharide, it cannot
be metabolised into monosaccharides and absorbed as there is no naturally
occurring lactulose enzyme present to perform this biological function.
Therefore, the lactulose travels intact to the colon where it is metabolised by
colonic bacteria. By this means, orocaecal transit time can be measured. In
rare instances, there are bacteria present in the colon which are unable to
breakdown the synthetic lactulose into fructose and galactose but these
bacteria are still capable of producing hydrogen (Eisenmann et al 2008).
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Glucose in general, is the most popular choice for detecting SIBO. It is readily
absorbed and is a more sensitive substrate. The sensitivity and specificity of
the lactulose HBT in detecting SIBO has been reported to be only 68% and
44% and for glucose HBT 62% and 83% (Simren and Stotzer 2006). There
are also a number of limitations to using lactulose substrate that may result in
false positive and false negative results (see Section 5.2).
The glucose HBT can also been used in other applications such as in patients
suffering from pancreatic insufficiency where it was shown be positive for
SIBO in 40% of patients. This was also the case in patients with liver cirrhosis
where up to 33% were found to be positive for SIBO (Eisenmann et al 2008).
In the Gastrointestinal unit, St. James’s Hospital, the HBT is also used to test
for

lactose

malabsorption,

fructose

malabsorption,

and

sucrose

malabsorption. The dose concentration of the solution consumed and the
length of time it takes to perform these procedures differs to that of the SIBO
test. The HBT is a simple technique to perform, inexpensive, non-invasive,
does not have any side effects, has several applications, and multiple studies
can be performed using the one HBT device at the same time.
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5.2 Values for detecting Small Intestinal Bacterial Overgrowth

The fasting baseline of expired hydrogen should be <10ppm (ideally <5ppm).
A high baseline may suggest slow intestinal transit whereby residual food is
still being metabolised or it may be due to the presence of SIBO. This
however is quite uncommon and is more than likely due to poor adherence of
the pre-procedure protocol to avoid high fibre foods the day prior to the HBT.
The glucose hydrogen breath test is considered positive if there is a clear
peak in measured hydrogen. Again, there is vast variability amongst users as
to what is the normal cut-off point. A majority of studies suggest that a
hydrogen peak exceeding 10-20ppm above baseline is indicative of a positive
glucose test (Simren and Stotzer 2006). While others suggest that any
increase over 10ppm above baseline is considered significant (Eisenmann et
al 2008; Croagh et al 2007). In our unit, we recommend that a rise of >12ppm
above baseline is indicative of SIBO, refer to Figure 5-1. Some other studies
suggest a similar protocol (Vanderhoof and Pauley-Hunter 2013b; Dukowicz
et al 2007).
Small intestinal bacterial overgrowth detection using lactulose is measured by
observing for a ‘double-peak’. An initial early peak of >12ppm within the first
60 minutes followed by a larger peak indicating that the lactulose solution has
reached the colon, refer to Figure 5-2 (DLGIP 2009). There are limitations to
this measurement. For example, it may be difficult to distinguish SIBO from
colonic fermentation if there is rapid transit and the effect of lactulose itself
must be considered as it increases intestinal transit. The detection of two
distinguishable peaks may also result in false positives if an initial bolus
reaches the caecum imitating the first peak before the rest of the luminal
contents reach the caecum producing the second peak (Simren and Stotzer
2006). Normally lactulose reaches the colon within 70-90 minutes (Eisenmann
et al 2008).
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Figure 5-1 - Normal and abnormal HBT using glucose substrate

Figure 5-2 - Normal and abnormal ‘ideal’ HBT using lactulose solution
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5.3 Factors affecting Hydrogen Breath Test analysis

Smoking and exercise are restricted before and during the study. Smoking
has the effect of raising the hydrogen concentrations while exercise lowers the
concentration of hydrogen measured (Simren and Stotzer 2006).
False negative results may occur in patients with gastrointestinal motor
disorders e.g. delayed gastric emptying in which case, the HBT may be
concluded before the substrate had the chance to reach the intestine. In
contrast, those with rapid transit through the small intestine may yield a false
positive result due to metabolism of the substrate by colonic bacteria. This is
because of the reduction in the time frame where the substrate makes contact
with the absorption mucosa. Subsequently, it is then transported to the colon
where metabolism occurs.
With regards with malabsorption studies as opposed to SIBO, there are
several addition potential errors that may exist in addition to those listed
above. These include patients that suffer from chronic pancreatitis and coeliac
disease (Simren and Stotzer 2006). This is because the release of enzymes
from the intestinal source is compromised leading to the inability of
disaccharides to be broken down into monosaccharides and therefore an
absorbable form.
The use of fructose as a substrate may be unreliable and difficult to interpret.
Fructose is found in many everyday foods and beverages as a sweetener. It is
also present in fruits such as apples, peaches, cherries and pears. Absorptive
capacity of fructose by carrier mediated facilitated diffusion varies greatly and
tends to be dose and concentration dependant. When fructose is ingested
with glucose, the absorption of fructose increases. However, when fructose is
ingested with sorbitol, the absorption of fructose decreases. In dietary
sources, both glucose and sorbitol are more likely to be found in combination
with fructose. Therefore, HBT using fructose alone does not reflect the normal
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dietary consumption of fructose ingestion (Simren and Stotzer 2006). Some
units use 50g of fructose dissolved in 250mls of water, but this does not
correspond to real physiological situations nor does it make a difference in the
results if 25g was used instead. In addition to this, it may lead to more side
effects during the study (Eisenmann et al 2008).
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5.4 Limitations in Hydrogen Breath Test

Glucose tends to be more sensitive in detecting SIBO compared to lactulose
solution. However, some argue that because glucose is absorbed in the
proximal part of the small intestine, SIBO investigation may result in a false
negative result. Lactulose on the other hand is a synthetic sugar and therefore
not absorbed. It travels distally, intact, to the colon where it is metabolised by
colonic bacteria. Therefore the lactulose solution travels the entire length of
the small intestine and in addition, has the ability to measure orocaecal transit
time.
A lack of hydrogen production can occur due to a predominance of intestinal
bacteria which metabolise hydrogen themselves. Some bacteria produce
methane from hydrogen (Dukowicz et al 2007). Bacteria that can contribute to
a lack of hydrogen production include; acetogenic bacteria, methanogenic
bacteria, nitrate-reducing bacteria, sulphate-reducing bacteria or it can be as a
result from the lack of hydrogen producing bacteria within the colonic lumen
(Ledochowski M and Ledochowski E 2008).
The analysis of methane gas can identify SIBO is those patients who are not
hydrogen producers. Methane breath testing can identify approximately 10%
more patients with SIBO when compared to the glucose hydrogen breath test
alone (Rusu et al 2012).
HBT using fructose substrate is absolutely contraindicated in those with
known or suspected hereditary fructose intolerance or in those with
postprandial hypoglycaemia (Eisenmann et al 2008).
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5.5

Gastro+ Gastrolyzer® measuring system

The Gastro+ Gastrolyzer ® (Figure 5-3) is intended for multi-patient use in a
clinical setting. The monitor is configured by uploading the patient’s data via a
USB port connected to a PC which has the GastroCHART PC software
installed. The device has a colour touch screen display and allows the user to
view results in a list or graphical configuration. It requires three AA alkaline
batteries to power the device.

Figure 5-3 - Gastro+ Gastrolyzer® measuring system
(Gastro+ Operating Manual 2014)

The Gastro+ must be switched on in fresh air to ensure an accurate zero
level. It is turned on by holding the on/off button until the display lights up and
becomes active. The unit will automatically power off after 45 minutes of
inactivity. A D-piece is then inserted into the slot on the device, Figure 5-4.
This D-piece is a one-way valve to prevent air being drawn back into the
monitor. The air passes through an infection control filter that removes and
traps >99.9% of airborne bacteria. It should be changed once a month or
when visibly soiled as it cannot be cleaned or sterilised. Between breath tests,
the D-piece should be removed to allow fresh air to circulate around the
hydrogen sensor (Gastro+ Operating Manual 2014).
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Figure 5-4 - D-piece
(Gastro+ Operating Manual 2014)

Figure 5-5 - Disposable mouthpiece
(Gastro+ Operating Manual 2014)
A single-use disposable cardboard mouthpiece is then slotted over the Dpiece and the connections firmly checked, Figure 5-5. The procedure is then
ready to be carried out according to the guidelines in Section 5.6.
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5.6 Hydrogen Breath Test procedure

The patients arrive to the GI Function Unit for SIBO investigations following a
strict 12hr fast. No antibiotics are permitted for at least four weeks before the
study and no colonoscopy should be performed at least one month prior to
this study. This is because of the reduction in the normal bacterial flora levels
in the colon.
Avoidance of high fibre foods the day prior to the test is another requirement
because these high fibre foods can cause prolonged hydrogen secretion and
elevate basal measurements (Vanderhoof and Pauley-Hunter 2013b). Other
food products that are also not advised include onions, leeks, garlic, cabbage,
beans or any pickled vegetable (Ledochowski M and Ledochowski E 2008).
Laxatives, in particular lactulose should be discontinued for at least 3 days
before HBT (Eisenmann et al 2008). Smoking and chewing gum should be
discontinued for 12hrs prior to study. Antimotility drugs are discontinued for
two days prior to the HBT.
The patient is asked to perform a preliminary mouth wash with a
chlorhexadine agent before a baseline breath sample is taken. This is to
ensure that oral bacteria do not cause false positive results and early elevated
measurements of expired hydrogen. The baseline breath sample should be
0ppm, but a baseline of up to 10ppm is considered adequate to continue with
the study (ideally <5ppm). If the baseline is >10ppm, it might be suggested
that the patient returns for their HBT on a subsequent day and follows a 16
hour fast. But this is quite dependant on individual cases and circumstances.
Following the baseline sample, the patient then ingests the appropriate
substrate (Table 5-1) and breath samples are taken at 15 minute intervals
over a two/three hour period. The data collected is then offloaded from the
Gastrolyser to the computer system, printed out and saved accordingly.
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Table 5-1 - Dose of substrate and preparation
Grams

Dissolved

50g

In 250 mls hot water and allowed to cool

Fructose 25g

In 250 mls hot water and allowed to cool

Glucose

Lactulose 10g/15 mls 250 mls of room temperature water

This volume (250 mls) of water is used because if the solution was too
concentrated, then there would be a larger non-absorbed proportion which
may result in a false positive test. In contrast, the smaller the concentration,
the better the absorption rate which may lead to a false negative result
(Ledochowski M and Ledochowski E 2008).
Hydrogen is distributed differently depending on the subjects’ position (Shelly
2009). During the study, the patient is asked to stay in the sitting position and
avoid exercise/walking throughout the investigation as it may hamper
collected samples of expired hydrogen. The HBT results are not affected by
the presence of other subject in the procedure room (Eisenmann et al 2008).
Even though, the HBT is a non-invasive and cost effective test when
compared to performing intestinal aspirates, it can be quite labour-intensive
with samples taken every 15 minutes over such long durations.
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5.7 Hydrogen Breath Test duration and sampling times

Published data on the optimal test duration is limited. A testing duration of 3
hours has being the longest reported time frame when testing for SIBO (Grace
et al 2012). A study from The Royal Marsden NHS Foundation Trust in
London showed that most patients testing positive for SIBO would do so by
the 100 minute mark. In this study, samples were taken every 20 minutes and
methane gas analysis was also performed (Grace et al 2012). Simren and
Stotzer (2006) documented that sampling for SIBO is usually every 15
minutes (Simren and Stotzer 2006).
For our investigations, we sampled at 15 minute increments over a two hour
period. This was following the protocols of published data and to ensure no
critical values of expired hydrogen were missed especially in those patients
with altered GI Physiology following upper GI surgery.
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5.8 Calibration of the Gastro+ Gastrolyzer®

Calibration should be performed once a month. If the calibration icon is
displayed on screen when the device is switched on, calibration is due. The
Gastro+ Gastrolyzer® should be calibrated at 21oC (±4oC). If calibrated at
lower temperatures, this may result in lower readings and vice versa.
The calibration gas used is 100ppm hydrogen in air. The device must be
zeroed in fresh air prior to calibration. The fine control valve (1) on the
hydrogen gas cylinder is turned to allow the gas to flow at 0.5 litres per
minute, Figure 5-6. The cylinder is connected to the D-piece on the monitor by
using calibration connection equipment between the two pieces. To maintain a
steady flow of hydrogen at this required rate of flow, the ball in the flow
indicator on the gas cylinder is kept at the lower line (2). The ppm value starts
to appear on screen.

Figure 5-6 - Calibration of HBT device using gas cylinder
(Gastro+ Operating Manual 2014)
If the final ppm reading is between 84-116ppm, the measurement will be
accepted and automatically set in the instrument as 100ppm.

62

5.9 How to exhale efficiently into Gastrolyzer

When a breath sample is taken, the ‘breath’ icon on screen is selected. This
initiates a countdown from 15 seconds. The patient is asked to hold their
breath based on a resting expiratory position rather than to take a deep breath
in (Ledochowski M and Ledochowski E 2008). The patient is asked to
continue to hold their breath until further instruction. An audible sound is heard
from the monitor for the final 3 seconds of the countdown which is also visible
on screen. At the final beep, the patient is asked to insert the mouth piece into
their mouth, close lip firmly around the disposable cardboard piece and exhale
slowly into the device, Figure 5-7 and Figure 5-8. The patient is encouraged to
expel the breath completely from their lungs. The ppm value will appear on
the display. This measurement is then saved manually by pressing the ‘save’
icon on screen.
In the case where patients are unable to tolerate the full breath hold, they are
asked to inhale and hold their breath for as long as possible and then exhale
into the mouth piece as described above.

Figure 5-7 - Screen display during breath sample
(Gastro+ Operating Manual 2014)
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A number of patients can be simultaneously tested on this device by
uploading all the patients’ data via GastroCHART and using the up and down
arrows on the monitor to select each patient when taking individual samples.
In our unit, we would not recommend performing any more than two
simultaneous recordings. The reason for this is because it takes time for the
hydrogen measurements to stabilise and this may result in an overlap of
timing between patients when sampling every 15 minutes. In addition to this, if
each or any of the patients are symptomatic with for example diarrhoea during
their study, it would be quite unpleasant for everyone in the clinical area,
especially if there are limited toilet facilities available.
Following the last breath sample, the data is then downloaded onto the
GastroCHART via a USB cable connected to the PC. The data is displayed in
both a graphical and tabular format and lists all the patients’ details. The
results are then printed and saved on both the local and hospital server in
PDF. If the monitor is not likely to be used for some time, it is recommended
that the batteries are removed. The hydrogen sensor should be replaced
every two years.

Figure 5-8 - Patient exhaling into Hydrogen Breath Test device
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5.10 Rational of research and control group
An audit of all referrals for Hydrogen breath testing (HBT) for small intestinal
bacterial overgrowth (SIBO) was carried out between 2008-2011. A total
number of 194 patients were tested for SIBO using glucose substrate and
fructose substrate. Some patients were tested on two different occasions with
both solutions. These patients were referred for differing reasons ranging from
patients suffering with acute/chronic diarrhoea, steatorrhoea and/or other
general abdominal/gastrointestinal disturbances. Patients were also referred
post-surgery for an oesophagectomy or gastrectomy who had difficulty gaining
weight or malabsorption issues.
A total number of 312 HBT’s were performed on these 194 patients (124
female vs. 70 male). Of these, 66 patients were positive (34%) for SIBO using
glucose substrate, fructose substrate or having been tested with both
solutions. Breath samples were taken at 20 minute intervals in accordance
with our unit protocol (during that period) over a duration of up to 2 hours.
The 194 patient cohorts was subdivided into two groups; a group of 22
patients for post Gastrectomy & Oesophagectomy (G & O) and a 172 patient
group with diagnosed or suspected Irritable Bowel Syndrome (IBS). Figure 5-9
illustrates a flow chart of this HBT patient audit which took place in the
Gastrointestinal function unit, St. James’s Hospital between 2008-2011 and
their positive HBT results.
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194 patients tested for
SIBO using HBT - 94%
positive

172 IBS Patients

22 post upper GI surgery
patients

28% positive for SIBO

82% postive for SIBO

Figure 5-9 – GI Function SIBO Audit 2008 – 2011

Figure 5-10 - Comparison between patient groups positive for SIBO
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The post-surgical group were broken down into oesophagectomy and
gastrectomy patients along with their corresponding positive HBT results
(refer to table 7.1). We found that 18 out of these 22 patients were positive for
SIBO using either glucose or fructose (82%).
Table 5-2 - Post Oesophagectomy/Gastrectomy patients and HBT
Results
Surgery Type

No. of patients Positive

% of Positive SIBO Test

Gastrectomy

7

6

85%

Oesophagectomy

15

12

80%

The glucose or fructose solution used to test for SIBO and the corresponding
positive glucose HBT result of this post surgical group of patients is listed in
Table 5-3.
Table 5-3 - Post Oesophagectomy/Gastrectomy patients tested for SIBO
Substrate

No. of studies Positive Percentage

Glucose

13

7

53%

Fructose

22

17

77%

9

6

67%

Both glucose and fructose

Fructose used in detecting SIBO in post upper GI surgery patients is
debatable as the reduced transit time could result in fructose malabsorption
being detected as opposed to SIBO. In most literature, glucose is the
substrate of choice for detecting SIBO. In the initial research figures below,
fructose breath tests were undertaken as the surgical team requested these
studies be performed to see if there was a malabsorption issue that was
associated with the patients’ symptoms. As the research progressed, glucose
was requested for SIBO. This was because patients found it too difficult to
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attend for both appointments and as fructose has its limitations; glucose was
the recommended testing substrate.
A study from the Sheffield Teaching Hospitals NHS Trust showed similar
results when they carried out a retrospective analysis of 447 glucose HBT’s
performed from 1998-2010. These results demonstrated 18.8% positive result
for SIBO when measuring both hydrogen and methane in exhaled breath
samples (Evans et al 2012). This finding was comparable with our data above
which showed an 8% positive SIBO finding when testing with glucose
substrate (in the 194 patient group above) using hydrogen gas analysis only.
In Section 5.4 ‘limitations of HBT’ it mentions that a further 10% of patients
may be identified as being positive for SIBO when methane gas analysis is
performed in conjunction with exhaled hydrogen.
Based on these HBT audit results which took place in the Gastrointestinal
function unit between 2008-2011, a comprehensive research study was
initiated to document hydrogen breath test findings in symptomatic patients
following

an

oesophagectomy

or

gastrectomy.

This

would

include

documenting the patients lifestyle habits, type of surgery, cancer morphology,
multimodal therapy, Barrett’s histology, and post-operative complcations.
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5.11 Patient Criteria for researched surgical group

Patients used in this research study were all referred to the GI Function Unit
by the Consultant Surgeon to establish the presence of SIBO. All patients
referred for HBT in this group received potential curative surgery to treat
oesophageal or gastric carcinomas.
The majority of patients referred were symptomatic following their surgery.
Chemotherapy and/or Radiotherapy before and/or after surgery was
performed in some patients as part of their multimodal treatment plan.
Patients were referred to the unit following their post-surgery clinic
appointment. During this clinic visit, the consultant and dietician assessed the
patient’s progress in terms of their nutritional status and clinical well-being
following surgery.
The exclusion criteria for this research group included those patients that:
• Had an oesophagectomy or gastrectomy for reasons which were not related
to a malignant tumour e.g. Achalasia
• Had their surgery prior to 2010
• The reconstructive part of the oesophageal or gastric surgery involved a
colonic transposition
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5.12 Data Collection - Patient Profiles
A new questionnaire was devised by the Gastrointestinal Function Unit for
patients attending for their Breath test, refer to Appendix 6. The timing
between samples was adjusted to shorter intervals of 15 minutes to reflect the
altered GI physiology in this group of patients.
Initially, the main challenge was the co-operation of patients to attend for
these tests, as they can each take up to 2hrs to perform. Most of these (68%)
patients attending for studies lived outside the catchment area for the Hospital
and would have to travel a lengthy distance for their procedures.
Therefore, we co-ordinated where possible, the patients’ Hydrogen breath test
to be followed by their clinic outpatient and dieticians appointment on the
same day. The patients would also receive their results on this day with the
surgical team and if necessary, prescribed antibiotics to treat the SIBO.
A total of 106 patients were tested for SIBO post oesophagectomy and
gastrectomy. The results of these tests are detailed in Appendix 1
The vast majority of patients in this group, 50% (n = 53) were greater than 66
years of age. Those patients aged 51-65 years represented 37% of this
cohort, while those aged between 35-50 years had a 12% presence. Only one
patient was younger than 35 years.
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Chapter 6
6 Data Analysis & Results
6.1 Hydrogen Breath Test Results

Of the 106 patients referred for this investigation, only 99 patients where
included in this study. Two patients had a colonic interposition rather than a
gastric conduit as part of their surgery. One patient refused the studies as he
found it would be too difficult to fast and travel to the hospital. One patient
subsequently passed away, one patient had total dysphagia and was unable
to consume the glucose solution, and two patients were non-cancer patients.
Of these 99 patients, 60 (61%) had a positive test. The percentage of patients
that were positive for SIBO were broken down into those that had an
oesophagectomy and those patient that underwent a gastrectomy. Figure 6-1
below lists the number of patients and the corresponding percentage of
positive HBT results.
Table 6-1 - SIBO in post gastrectomy and oesophagectomy patients

Surgery Type

No. of patients Positive

% of Positive
SIBO Tests

Gastrectomy

38

20

53%

Oesophagectomy

61

40

66%

The percentage of positive HBT results for SIBO were then analysed by the
sugar substrate used for testing in this group of surgical patients. Table 6-2
below shows these findings.
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Table 6-2 - Substrate used for SIBO and their positive percentage
response
Substrate

No. of studies Negative Positive % of Positive SIBO Tests

Glucose

93

44

49

53%

Fructose

54

26

28

52%

Both glucose and fructose

48

31

17

35%

The timeframe and corresponding positive HBT results of when these patients
were tested for SIBO post-surgery was analysed (refer to Table 6-3). Those
patients that were tested 7-12 months post-surgery had an 85% positive SIBO
result.
Table 6-3 - Duration (months) that patients were tested for SIBO post
surgery
Time post op (mths) No. of studies Positive % of Positive SIBO Tests
1-6 mths

59

32

54 %

7-12 mths

27

23

85 %

>1 year

13

5

38 %
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6.2 Repeat Hydrogen Breath Tests post Antibiotic Therapy
If the patients obtained a positive result for bacterial overgrowth, the surgical
team assessed their clinical response and decided on an appropriate
antibiotic therapy for the patient. The patient was prescribed Rifaximin 400mg
QDS PO for seven days. A total of 12 patients that were positive for SIBO
were prescribed antibiotics and were referred back to the GI unit for re-testing
(refer to Table 6-4). Retesting involved having a repeat glucose HBT
performed using the same technique as described in section 5.6.
The remaining patients were either treated with antibiotics and clinically
assessed for response to therapy rather than a re-test; or not treated with
antibiotic therapy because the team recognised a clinical improvement since
their last out-patient appointment, (patient felt symptoms are improving and/or
patient weight had increased). For these patients, a follow-up clinic
appointment for 6/12 months was arranged to re-assess the patient’s wellbeing, and if at this stage the patient’s response was deteriorating or
symptoms were worsening, then treatment with antibiotics would be
considered.
Patients that received antibiotic therapy were sent appointments to return to
the GI unit for follow-up retesting approximately 8-10 weeks post antibiotic
therapy. To date a total of 12 patients returned for retesting post antibiotic
therapy. Nine patients showed a marked improvement in symptoms and had
gained some weight.
The patients were retested using the same protocol and timing between
samples. Once again, the patient would return to the clinic after their test
ended for the team to decide on their treatment, taking into account the
patients clinical response, their improvement if any following antibiotic
therapy, their retest results and if their weight had increased. Seven patients
remained positive post antibiotic therapy, but their ppm value was drastically
reduced indicating that there was a response to antibiotic therapy. The results
of those patients that were now negative post antibiotic treatment were
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analysed according to weather that had underwent an oesophagectomy or
gastrectomy (refer to Table 6-5). As these patients showed a marked
improvement post therapy, a second dose of antibiotics was not prescribed
but the patients were given an appointment to return to the outpatient clinic in
6/12 months for review.
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Table 6-4 - Patients retested post antibiotic therapy
Clinical
Patient Improvement
No.
PA

Retested
(mths) PA

Substrate patient
retested for

Positive
SIBO PA

4

Yes some

7

Glucose, fructose

Yes

5

No

8

Glucose, Fructose

Yes

9

No

7

Glucose, fructose

Yes

17

Yes

2

Glucose x 2,
Fructose

Yes first
therapy &
negative 2nd
therapy

24

Yes

2

Glucose, Fructose

No

25

Yes

2

Glucose, Fructose

No

26

Yes

2

Glucose

Yes

27

Yes initially

2 and 10 (one
antibiotic)

Glucose, Fructose

Yes on both
retests

28

Yes

2

Glucose, Fructose

No

37

Yes

(1)3 weeks ,
(2) 3mths, (3 )
6mths

Fructose, Glucose

Yes first two
& negative
last repeat

39

Yes, initially

2 and 3 weeks Glucose x 2 repeats

50

Some then
symptoms
returned for
2nd repeat

3 months and
2nd repeat 2
months post
abx

Glucose

Yes for both

Yes both
occasions

PA - Post Antibiotic Therapy. Out of these 12 patients who were retested for
SIBO, 5 were now negative for SIBO and 7 patients were still positive for
SIBO.
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Table 6-5 - % of patients negative for SIBO post antibiotic therapy

Surgery Type

No. of
patients

Negative post
treatment

% of Positive
SIBO Tests

Gastrectomy

4

1

25 %

Oesophagectomy

8

4

50 %

All patients post
therapy

12

5

42 %
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6.3 Comprehensive breakdown of patient data cohort

A comprehensive analysis was performed to determine whether there were
common factors amongst those patients who proved positive for SIBO. A
detailed history of the patients treated and their diagnosis was obtained and
scrutinised. From this group of 99 patients, 94 patients were studied. The five
patients excluded consisted of four patients that were diagnosed with noncancerous GIST, and one patient that had an oesophagectomy for treatment
of Achalasia.
This group of patients that were tested for SIBO post-surgery for an
oesophagectomy or gastrectomy as a result of carcinoma were categorised
firstly by gender, age at diagnosis, BMI at diagnosis and symptoms
experienced at diagnosis as a result of their illness/surgery.
Breath test results for glucose were analysed in this group as it was the
substrate that was used in 93% of subjects and is considered to be the gold
standard. For purposes of this part of the study as it is quite specific,
standardization and comparability of patient data was performed. The data
collected is shown in Appendix 2. As mentioned in Section 5.10, the use of
fructose in detecting SIBO is debatable; this is because the reduced transit
time in this group of patients could result in the rapid emptying of the fructose
substrate into the large intestine before it can be absorbed. It could also be as
a result of reduced or diminished fructose transport carriers due to intestinal
damage/inflammation. This would result in fructose malabsorption as opposed
to SIBO. In this instance, we suggested a positive fructose result of SIBO if
there was a very early rise in the ppm value. Therefore, it was recommended
to the team that only glucose be performed if SIBO is to be examined.
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6.3.1 Mean age of group and their associated HBT result

The average age at diagnosis was 63.38 years. This ranged from 34 to 83
years of age. The average age for females at diagnosis was 62.5 years (n =
30) and for males was 63.8 years (n = 64). Those patients that had a positive
HBT had a mean age of 62.8 years, while those with a negative HBT had a
mean age of 63.94 years.

There were no significant differences in the median age of patients with
positive vs negative breath tests. Independent sample Mann Whitney U tests:
Age: p=0.812
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6.3.2 Symptoms Experienced

There were 266 symptoms in total experienced by this patient group (refer to
Figure 6-1). Four of these patients did not experience any symptoms what so
ever, their diagnosis was through an incidental finding.
The most common symptom experienced by patients was Dysphagia (n=49),
followed by weight loss (n=37). The ‘other’ symptoms (n=13) experienced by
these patients included: chest pain, flank pain, retro-sternal pain, waterbrash,
back pain, cough, gastric outlet obstruction, pulsating lump in abdomen, night
sweats, and hair loss.

Figure 6-1 - Symptoms Experienced
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6.3.3 BMI and Hydrogen Breath Test Result

Some patients (n=19) that were referred from tertiary centres did not have
their BMI documented at the time of diagnosis. BMI was documented at the
time of diagnosis in the remaining 75 patients (56 males, 19 females). The
average BMI in this group was 27.08. The average BMI for females was 24.38
and for males, 28.06.
Normal BMI was marked as being between 18.5-25, overweight 25-30, obese
30+ and the underweight category was reported with a BMI of <18.5. Table
6-6 lists the number of patients in each of these BMI indices and their
corresponding positive HBT result.
Table 6-6 - BMI of Patient Group
% of Positive
Males SIBO Tests

BMI Index

Females

<18.5

3

1

5%

18.5-25

10

16

35 %

25-30

3

18

28 %

>30

4

20

32 %

Out of 75 patients who had their BMI Documented at time of diagnosis, 60%
were classified as being overweight or obese. In males alone, 68% were
documented at having a BMI of >25. In the female group, 37% had a BMI of
>25.
A total of 70 patients with documented BMI had glucose HBT studies
performed. Of these patients, Figure 6-2 shows the positive response rate
with the corresponding BMI bracket for the combined female and male group.
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Figure 6-2 - BMI and corresponding glucose result for both female and
male group.

Figure 6-3 - Figure BMI and positive/negative glucose Hydrogen Breath
test.
There was no significant difference (Pearsons Chi-square test): 0.067
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The median BMI of patients with a positive breath test was 24.86 (range:
17.47-42.75) versus median 29.22 (19.11-40.82) for patients with a negative
HBT. This was significantly different (p=0.012, independent samples MannWhitney U test).
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6.3.4 Smoking and Drinking Habits

Out of these 94 patients, 50 patients were ex-smoker, 15 current smokers, 27
patients never smoked and 2 patient’s smoking history were not documented.

Ex-drinkers were documented in 6 patient profiles, 12 patients were heavy
drinkers, 59 patients were social drinkers, 14 non-drinkers and 3 patients
drinking history were not documented. The number of patients and their
smoking and drinking habits is demonstrated in Figure 6-4 below.

Figure 6-4 - Smoking/Drinking History
Seven patients did not attend for their glucose breath test. These patients
were all tested for SIBO using fructose substrate and observed for an early
rise in exhaled hydrogen in breath samples. There were varying reasons why
these patients did not attend for their glucose breath test including poor
health, travelling difficulties, challenges with fasting instructions etc.
Therefore, 87 patients were tested for SIBO post major upper GI surgery
using glucose substrate.
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Out of these 87 (60 males, 27 females) patients who were tested with glucose
substrate, 46 patients (53%) were positive for SIBO (refer to Table 6-7).
Table 6-7 - Results of glucose breath test
Positive Glucose HBT

Negative Glucose HBT

Total

53% (n=46)

47% (n=41)

Male

43% (n=26)

57% (n=34)

Female

74% (n=20)

26% (n=7)

Female patients were significantly more likely to have a positive HBT than
male patients (74.1% versus 43.33%, p=0.011).
Ex-smokers dominated this category representing 56% of patients. Of this, exsmokers had a 42% positive percentage rate. Non-smokers represented 26%
of patients and had a 73% positive result for SIBO using glucose substrate.
Current smokers, 18% of group, had a 60% positive glucose BT result.
Smoking history and the corresponding positive glucose HBT results are
shown in Figure 6-5. There were 2 un-documented patient files. Therefore,
those patients that never smoked were more likely to have a positive HBT
(72.7%) vs. patients who were either current or ex-smokers (46.2%, p=0.047).
The odds ratio for those patients that were smokers having a positive HBT
versus those patients that never smoked is OR = 0.678 (95% Cl; 0.16, 2.85).
The entire ex-smokers group smoked cigarettes only. The average amount of
cigarettes smoked per day was 27. This value ranged from 1-100 cigarettes
per day. The average amount of years that these patients smoked for was
27.83 years. This ranged from 2 years right through to 50 years of smoking.
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Percentage of Positive Glucose HBT Results

Smokers/Non-Smokers/Ex-Smokers vs
Positive BT Results
73%
80%

60%

70%
60%

42%

50%
40%
30%
20%
10%
0%
Ex smoker

Never Smoked

Smoker

Figure 6-5 - Smokers/Non-Smokers/Ex-Smokers vs Positive BT Results.
The ‘Never smoked’ group were more likely to have a positive HBT (72.7%)
vs. patients who were either current or ex-smokers (46.2%), p=0.047.
Social Drinking was defined by: <14 units per week for females and <21 units
per week for males. Social drinkers were highly represented within this group,
accounting for 65% of the total. Out of this, 53% had a positive breath result
using glucose substrate. Non-drinker totalled 15% of the group and had a
positive breath test result of 77%. Next were the ‘heavy drinkers’ at 12% of the
group and had a positive result of 30%. Finally, the ‘ex-drinkers’ at 7% of the
group had a 33% positive breath test result. Drinking habits and the
corresponding positive breath test results are shown in Figure 6-6. ‘Nondrinkers’ were more likely to have a positive HBT (76.9%) vs heavy drinkers
(30%), p=0.032. The odds ratio for those patients that were drinkers having a
positive HBT versus those patients that were non-drinkers is OR = 0.28 (95%
Cl; 0.07, 1.12) while the odds ratio for those patients that were heavy drinkers
having a positive HBT versus those patients that were social drinkers is OR =
0.48 (95% Cl; 0.11, 2.13).
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Patients who were documented as being heavy drinkers, consumed up to 50
units of alcohol per week. Those patients who were noted as ‘ex-drinkers’ all
had a history of alcohol dependency.

Figure 6-6 - Drinking Habits vs Positive BT results.
Non-drinkers’ were more likely to have a positive HBT (76.9%) vs heavy
drinkers (30%), p=0.032

86

6.3.5 Disease recurrence and malignancy history

Post-Surgery, 11 (13%) patients died as a result of disease recurrence. A
further 10 (11%) patients are alive with disease while the remaining 66 (76%)
patients have showed no evidence of disease recurrence to date.
Of these 87 patients who were tested for SIBO using Glucose, 64 (74%)
patients

had

no

known

previous

malignancies.

Malignancies

were

documented in 22 (25%) patients (refer to Figure 6-7). One patient’s
malignancy history was not documented.
Out of these 22 patients who had a previous history of malignancy, ten
different cancer types were documented.

Figure 6-7 - Types of Previous Malignancy
From this group of patients who had a previous history of malignancy, two
patients (9%) were documented as currently having disease, while two (9%)
morbidity cases were reported from those patients who had a previous cancer
diagnosis.
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Figure 6-8 - Malignancy History Vs SIBO.
Those patients with a previous history of malignancy (n=22) had a positive
glucose breath test of 64% while those without a previous diagnosis of
malignance had a positive glucose result of 50%. Malignancy history and the
corresponding positive glucose HBT result is shown in Figure 6-8. Patients
with a previously diagnosed malignancy were no more likely to have a positive
HBT than patients without a history of malignancy (63.3% vs 50%, p=0.326).
The odds ratio for those patients that had a history of previous malignancy
having a positive HBT versus those patients that had no previous malignancy
history is OR = 1.75 (95% Cl; 0.65, 4.74).
The majority of patients who had a previous malignancy documented where
not GI related.
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6.3.6 Barrett’s Histology

Barrett’s histology was recorded in 67 patients (refer to Figure 6-9). Out of this
group, 43 patients had no known Barrett’s diagnosed either before or during
evaluation of their oesophageal cancer. Patients with known Barrett’s
oesophagus on diagnosis of cancer, accounted for 19% (n=13) of this group,
while 16% of patients were found to have a Barrett’s oesophagus when
undergoing evaluation for their cancer.

Figure 6-9 - Barrett's Histology
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Figure 6-10 - SIBO in patients with and without diagnosed Barrett’s
Oesophagus
Patients with Barrett’s oesophagus were no more likely to have a positive HBT
in the post-operative period (45.8% vs 48.8%, p=1.00). The odds ratio for
those patients that had documented Barrett’s Oesophagus having a positive
HBT versus those patients that had no documented Barrett’s Oesophagus is
OR = 0.89 (95% Cl; 0.33, 2.41).
There were 67 patients in total with documented Barrett’s histology results. Of
those diagnosed with Barrett’s oesophagus, 46% were positive for SIBO.
Those patients that were documented as not having Barrett’s oesophagus
showed a 49% positive response for SIBO using glucose substrate. This is
demonstrated in figure Figure 6-10 above.

90

6.3.7 Tumour Site and Morphology

The Oesophageal gastric junction was the most common location of tumour
findings and this was the case in 54 patients representing 62% of this group
(refer to Figure 6-11). This was followed by tumours located in the mid and
distal oesophageal body, accounting for 8% and 9% of the group respectively.

Figure 6-11 - Tumour Site

Adenocarcinoma was diagnosed in 89% of cases (n=76). The morphology
was not documented in two cases. Surgery was performed on all 87 patients.
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Figure 6-12 - Cancer cell morphology Vs positive glucose study.
The 76 patient group that were documented as having an adenocarcinoma
showed a 54% positive result for SIBO. Those patients with diagnosed
squamous cell carcinoma displayed a 44% positive result for SIBO (refer to
Figure 6-12). There was no significant differences noted according to
histological subtype (positive HBT rate in adenocarcinoma vs squamous cell
carcinoma: 53.9% versus 44.4%, p=0.729).
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6.3.8 Treatment type and intent

Over half of this patient group (51%, n = 44) had both surgery and neoadjuvant therapy, while 47% (n = 40) had surgery alone as their primary
curative treatment. Surgery and adjuvant therapy was performed in 2% (n = 2)
of patients from this cohort. One patient who received neo-adjuvant therapy
also went on to receive adjuvant therapy.
Most of these surgical cases (95% n = 83) had a curative intent. However, the
surgical outcome in 3 (4%) cases was uncertain and in one case it was
decided to perform surgery for palliative care. Out of the 3 uncertain cases, 2
patients now show no evidence of disease recurrence while the other patient
is alive with disease.
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6.3.9 Post Surgery outcomes and complications

The graph shown in Figure 6-13 demonstrates the correlation between the
type of oesophageal and gastric surgery and the associated post-surgery
complications and breath test results.
Transhiatal oesophagectomy and 2-stage oesophagectomy were the GI
surgical procedure that correlated to the highest complications post
operatively. Similarly, breath test results in 2-stage (60%) and 3-stage
oesophagectomy’s (67%) were represented by the highest positive results.
* Since only one patient had undergone a partial gastrectomy, this patient’s
result is not listed in the top two groups above.

Figure 6-13 - Post Surgery and BT Outcomes
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Figure 6-14 - Surgery Type vs Glucose BT.

Figure 6-14 above shows the collective surgical numbers when categorised
into oesophagectomy or gastrectomy groupings, and their corresponding
positive glucose HBT results. The four patients that were documents as
having an Oesophago-Gastrectomy were placed in the gastrectomy group
above. Those patients who underwent an oesophagectomy (n=55) showed a
56% positive glucose result while those patients who had a gastrectomy
(n=32) performed had a 47% positive glucose result. The proportion of
patients who had a positive HBT did not significantly differ whether they had
previously had an oesophagectomy versus a gastrectomy, p=0.682.
Complications post operatively occurred in 57 patients. Of these, 5 patients
had to return to theatre and 5 patients had a return stay in the High
Dependency Unit (HDU) and/or Intensive Care Unit (ICU). The 30 patients
who had no recorded complications post operatively had no further theatre or
HDU/ICU admissions.

95

Figure 6-15 - Post – Op complication Vs SIBO detected by HBT

A total of 57 patients suffered from post-surgery complications and of these
54% were positive for SIBO using glucose substrate. SIBO was evident in
47% of patients that did not suffer from any major post-surgery complications
(refer to Figure 6-15).
Patient who had post-operative complications were no more likely to have a
positive HBT than patients who did not suffer a post-operative complication,
p=1.0. The odds ratio for those patients experiencing post-operative
complications having a positive HBT versus those patients with no postoperative complications is OR = 1.36 (95% Cl; 0.56, 3.31).
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Of the 57 patients who had post-op complications, 97 complications were
recorded. From this, respiratory infections were the most commonly reported
complication (23%). This was followed by cardiac arrhythmias and respiratory
failure at 19% and 11% respectively. Figure 6-16 lists the complications
experienced in this patient group post-surgery and the number of patients
affected by each of these complications.

Figure 6-16 - Post Surgery Complications
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6.3.10 Chemotherapy and Radiotherapy received

Figure 6-17 - Radiotherapy Received.
Patients who had radiotherapy (52.5% vs 48.9%, p=0.682) were no more
likely to have a positive HBT than patients who had surgery alone. The odds
ratio for those patients undergoing radiotherapy having a positive HBT versus
those patients that had no radiotherapy is OR = 1.13 (95% Cl; 0.43, 3.01).
The radiation used in all cases was external beam (electrons) and the dose
ranged from 13-45 Gy.
A total of 25 patients were documents as having radiotherapy before and/or
post-surgery. Of these, 52% were diagnosed as having SIBO. Those patients
that did not receive radiotherapy (n=45) had a 49% positive detection rate for
SIBO using glucose substrate. Figure 6-17 displays the radiotherapy
treatment received and corresponding positive glucose HBT result.
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Figure 6-18 - Chemotherapy Received.
Patients who had chemotherapy (57.1% vs 53.1%, p=0.82) were no more
likely to have a positive HBT than patients who had surgery alone. The odds
ratio for those patients undergoing chemotherapy having a positive HBT
versus those patients that had no chemotherapy is OR = 1.18 (95% Cl; 0.48,
2.88).
The chemotherapy regime and number of cycles administered varied widely
amongst the patients receiving therapy.
A total of 49 patients received chemotherapy prior to their surgery. Of these,
57% were positive for SIBO using glucose substrate. Patients who did not
receive any chemotherapy (n =32) showed a 53% positive response to
glucose HBT. Those patients that received or did not receive chemotherapy
and their corresponding positive glucose HBT results are displayed in Figure
6-18.
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Neither patients who had radiotherapy (52.5% vs 48.9%, p=0.682) nor
chemotherapy (57.1% vs 53.1%, p=0.82) were more likely to have a positive
HBT than patients who had surgery alone.
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6.3.11 Post-Surgery Hospital Stay

The length of stay in hospital following surgery varied from 8 to 67 days. As
can be noted from Figure 6-19, the longer the length of stay in hospital
corresponded to the highest percentage rate of post-op complications e.g. of
the 12 patients who were in-patients for 24-27 days, 11 of these were noted to
have post-op complications.
The average length of stay was 20.64 days and the median was 17 days stay
in hospital following their upper GI Surgery. The standard deviation was
11.718
Similarly, this was the same pattern for the glucose results, as demonstrated
in Figure 6-19 and Figure 6-20. The longer the length of stay in hospital postop, the rate of positive glucose breath tests appeared to increase. However,
there were no significant differences in the median length of stay of patients
with positive vs negative breath tests. Independent sample Mann Whitney U
tests: Length of stay p=0.676
There was no apparent pattern with the association of hospital stay versus
type of surgery. However, it was noted that the least days spent in hospital
post-op, were occupied by those patients who had a total gastrectomy. These
3 patients spent 8, 9 and 9 days in hospital following their surgery.
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Figure 6-19 - Hospital stay post surgery

Figure 6-20 - % Positive Glucose Test
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6.3.12 Diabetic patients and Small Intestinal Bacterial Overgrowth

Figure 6-21 - Diabetic patients and SIBO

Patients without any documented diabetes (n=76; 87%) made up the majority
of this patient cohort. These patients showed a 55% positive response for
SIBO. Diabetic patients (n=11) had a 36% positive glucose result (refer to
Figure 6-21). Therefore, even though diabetes is thought to be a contributing
factor in the development of SIBO, it did not seem to be the case from the
data shown above in this surgical group. The odds ratio for those patients with
diabetes having a positive HBT versus those patients with no diabetes is OR
= 0.46 (95% Cl; 0.96, 2.80).
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6.4

Incremental Time Sample Analysis of HBT results from
patient cohort

Seven patients did not have a glucose breath test performed. This was
because their fructose breath test was performed first and the patient did not
want to return for further testing. Out of those patients that were only tested
using fructose, 7 (100%) patients were positive for small intestinal bacterial
overgrowth. The reason it was documented as being positive for SIBO as
opposed to Fructose malabsorption was because of the early H2 rise in
exhaled breath in all 7 patients. These positive tests showed a rise of >12ppm
within 60 minutes in 5 patients and within 75 minutes in one patient (refer to
Figure 6-22).

Figure 6-22 - Measured Breath Hydrogen (ppm)
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A total of 87 patients had a glucose breath test performed. Table 6-8 lists the
number of patients with positive and negative glucose HBT results. In total 46
patients (53%) tested positive for SIBO using the glucose HBT.
Table 6-8 - Glucose breath tests performed
Glucose
BT

Total No. of
Patients

% of Positive
Glucose HBT’s

Positive

46

53%

Negative

41

47%

Of those 87 patients that were tested for SIBO using glucose, the time frames
at which point the patients were positive for SIBO is listed in Table 6-9 below.
Those patients that had their HBT performed 7-12 months post-surgery, has
the highest positive response for SIBO at 73%
Table 6-9 - Duration (months) that patients were tested for SIBO post
surgery
Time post op
(mths)

No. of
studies

Positive

% of Positive
Glucose HBT’s

1-6 mths

55

25

45%

7-12 mths

22

16

73%

>1 year

10

5

50%
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Table 6-10 below lists the 15 minute sampling increments and the
corresponding positive glucose HBT result. Out of 46 patients positive for
glucose breath tests, 96% had a positive rise within 75 minutes, 93% within 60
minutes, 85% within 45 minutes, 59% within 30mins and 24% within 15
minutes. The average time that patients were likely to show a positive result
was 36.52 minutes.
Table 6-10 - Number of patients positive for glucose BT within specific
time frame
Time
(Minutes)

No. of Patients positive for
glucose BT

% of Positive Glucose
HBT’s

15

11

24%

30

27

59%

45

39

85%

60

43

93%

75

44

96%

90

46

100%
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6.5

Summary

Patient data was analysed in multiple categories ranging from body mass
index and diagnosed malignancy, to their hospital stay and complications
post-surgery. Table 6-11, Table 6-12 and Table 6-13 lists a summary of the
findings discussed and displayed in chapter 8.
Table 6-11 - Summary of patient data and their Glucose BT result
Details

BMI

<18.5

1

0

100

18.5-23

19

7

73

25-30

9

10

47

>30

11

13

46

Non-smoker

16

8

76

Current Smoker

9

6

60

Ex-smoker

20

28

42

Non-Drinker

10

3

77

Social Drinker

29

26

53

Ex-Drinker

2

4

33

Heavy Drinker

3

7

30

Smoking Habit

Drinking Habit

Positive (n) Negative (n)

Positive
Glucose %

Category
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Table 6-12 - Summary of patient data and their Glucose BT result
Positive
Positive (n) Negative (n) Glucose
%

Category

Details

Previous
Malignancy

Previous
malignancy

14

8

64

No malignancy hx

32

32

50

No Barrett’s
Oesophagus

21

22

49

Barrett’s
Oesophagus

11

13

46

Adenocarcinoma

41

35

54

Squamous cell
carcinoma

4

5

44

Oesophagectomy

31

24

56

Gastrectomy

15

17

47

Complications

31

26

54

No Complications

14

16

47

Non-Diabetic

42

34

55

Diabetic

4

7

36

Barrett’s Histology

Tumour
Morphology

Surgery Type

Post-op
complications

Diabetes
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Table 6-13 - Summary of patient data and their Glucose BT result
Details

Radiotherapy

Radiotherapy

13

12

52

No Radiotherapy

21

22

49

Chemotherapy

28

21

57

No Chemotherapy

17

15

53

08-11

6

9

40

12-15

6

12

33

16-19

13

9

59

20-13

3

2

60

24-27

9

3

75

28-39

5

5

50

40-50

1

0

100

51-60

1

1

50

61-70

2

0

100

Chemotherapy

Hospital Stay (days)

Positive (n) Negative (n)

Positive Glucose
%

Category
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Chapter 9
7 Discussion
A retrospective analysis of hydrogen breath testing (HBT) was performed over
a three year period from 2008-2011 on all patients investigated in the GI
Function unit. A total number of 194 patients who underwent 312 Hydrogen
breath test procedures were reviewed. Results from this audit indicated a high
positive rate for Small Intestinal Bacterial Overgrowth (SIBO) amongst those
patients with a history of surgery for an oesophagectomy or gastrectomy.
This 194 patient cohort was divided into two patients groups; those referred
with IBS symptoms (n = 172), and those referred post major upper GI surgery
(n = 22). Patients who had a HBT performed post oesophagectomy or
gastrectomy had an 82% positive SIBO test result.
Based on these findings, a comprehensive analysis of hydrogen breath testing
was carried out on a group of patients post oesophagectomy and
gastrectomy. Exclusion criteria for this new research group included those
patients that had complicated reconstructive surgery such as a colonic
transposition, those patients that had their surgery for a non-malignant
carcinoma such as a GIST or for Achalasia, and those patients that had their
surgery prior to 2010. The timing between breath samples was reduced from
the standard protocol of 20 minutes to 15 minutes to reflect the altered
physiology of this patient group. A total of 106 patients were investigated for
SIBO post oesophagectomy and gastrectomy. Of these, 99 patients were
suitable for review in this research. Patients were investigated with both
fructose and glucose substrate. Both of these substrates yielded similar
results when testing for SIBO. The overall positivity for SIBO was 61% and 12
of these patients that were prescribed a course of Rifaximin 400 mg TDS
returned to the GI unit for retesting and least one month after their antibiotic
therpy was completed. Of these 12 patients that were retested post therapy,
42% were now negative for SIBO.
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Following the results of this data, a third study group was initiated. A particular
emphasis was placed on those patients (n=87) that had a glucose breath test
performed. Results from these patients that had a glucose HBT performed
was used for comprehensive analysis as the risk of false positive results was
much lower than with fructose substrate. This is partly due to the potential
post-surgical complication of dumping syndrome which could lead to a result
of fructose malabsorption as opposed to SIBO. It can also be due to
diminished fructose carriers resulting from intestinal inflammation. As part of a
literature review conducted in this research, glucose substrate tends to be the
standard practice in most GI units including the Royal Marsden Hospital in
London, a specialist cancer centre.
Clinical and surgical data was scrutinised to try and establish a more efficient
practice for HBT procedures. This group of patients are a challenging cohort
who have had major reconstructive surgery of the GI tract, and have gone on
to develop malabsorption and malnutrition difficulties. This has had a major
impact on their quality of life post-surgery. The main focus of this study was to
establish the incidence of SIBO in this patient group and develop a streamline
protocol. There is no published data on this aspect of SIBO to date, so by
creating a more patient friendly protocol, progress post-surgery can be
managed more effectively though multi-disciplinary resources. Enhancement
of such protocols was successfully demonstrated through the findings in this
report and is now being implemented in the GI department.
A detailed review of this audit revealed that those patients who had a normal
or low BMI were more positive for SIBO than those patients who were
classified as being in the over-weight and obese categories. Similarly, those
patients who were non-drinkers and non-smokers also had a higher positive
glucose result compared to those patients who were current, ex or heavy
smokers/drinkers, these trends did show a statistical significance. Lifestyle
therefore did not seem to impact the overall glucose HBT result. Surprisingly
there was a tendency for more normalisation of results with those patients
who had poor lifestyle habits.
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Diabetic patients had a notably lower positive result when compared to nondiabetic patients. This is consistent with the other lifestyle patterns and BMI
discussed above. In contrast, those patients who had a history of previous
malignancy and post-op complications showed a higher result for SIBO. This
was also the case for patients who received multimodal therapy prior to their
surgery but these findings are not statistically significant. Studies have shown
that chemotherapy and radiotherapy can contribute to the development of
SIBO. This was emphasised in this research and highlights the need for a
prospective study on SIBO in patient’s pre and post chemoradiotherapy. The
length of hospital stay post-surgery reflects the SIBO results obtained.
Overall, those patients who spent the least amount of time in hospital
following surgery, i.e. a faster recovery period, were least likely to be positive
for SIBO when compared to those patients who had a longer in-patient stay.
Again, these trends did not show a statistical significance.
Overall, of the 87 patients who had a glucose HBT performed, 53% were
positive for SIBO. When broken into time frames, 45% were positive when
tested within 1-6 months of surgery. 73% were positive for SIBO when tested
within 7-12 months of surgery and 50% were positive when tested for SIBO
using glucose substrate after 1 year post surgery. As discussed in section
2.1, MMC’s are an important contributing factor for small intestinal motility. It is
thought that MMC disruption following surgery may take time to regulate and
accommodate to the altered physiology. It may therefore be more beneficial to
test patients for SIBO (unless very symptomatic) after approximately 12
months following surgery to allow for the MMC’s to normalise and perhaps
alter the small intestinal flora with its clearance function (Lawlor 2000).
Table 6-10 shows the 15 minute time segments and the corresponding
positive percentage rate for SIBO. From the data shown, by the 45th minute
marker, 85% of those patients with SIBO showed a positive result. This
increased to 93% by the 60th minute. All patients that were positive for SIBO,
showed a ppm rise of >12 by 90 minutes. The average time for patients to
show a positive SIBO test was 36.52 minutes. Poor patient co-operation is
one of the main disadvantages of the HBT due to time consumption, therefore
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changing the timing protocol for the glucose HBT can be suggested.
Currently, patients are informed that their glucose HBT can expect to take two
hours with samples being taken at 15 minute intervals. From these findings, it
was suggested that the HBT should take no longer than 90 minutes with the
data trend indicating that the HBT will be terminated within 60 minutes if there
is a rise of >12ppm. These changes have now been implemented in the GI
Function Unit and have been captured by the local oesophageal cancer
programme.
False positive breath tests can occur due to rapid intestinal transit (dumping
syndrome). Therefore an early rise (within 60 minutes) is more likely to be due
to SIBO than fermentation by colonic bacteria. This data can be used in
conjunction with clinical symptoms and response to antibiotic therapy to aid
diagnosis. Non-hydrogen producers may result in false negative results. This
is thought to be in the region of 10%. The prevalence of SIBO post-surgery
using glucose solution is comparable to the study by Paik et al. However, the
overall positive result for SIBO using glucose was lower in our study (53% Vs
78%). This accountable difference may be due our inability to measure
exhaled methane. In addition to this, the researchers used a different
approach to their method of investigation. For example, they allowed their
patients to smoke up to 30 minutes prior to their study which is known to
increase hydrogen concentration levels in the blood. They also used a higher
challenge dose of glucose (75g), took duplicate samples using different
measurement devices and they had multiple exclusion criteria e.g. only
gastrectomy patients with no evidence of disease recurrence for at least 6
months were included in study. We investigated patients from as early as 4
months following surgery. Both this study and my research showed similarities
in the time segments for SIBO to be diagnosed. At 60 minutes post glucose
ingestion, 100% of patients with positive HBT’s showed a positive result, while
we reported a 94% positive response for the same time segment. There is
limited data and research done on SIBO in patients following an
Oesophagectomy and Gastrectomy.
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In patients with negative Hydrogen breath tests who are symptomatic with
chronic diarrhoea, bile acid malabsorption (BAM) should be considered as a
cause for their symptoms. This can be examined by performing a SeHCAT
test. SeHCAT (tauroselcholic [75selenium] acid) is a radiopharmaceutical that
is used for detecting bile acid malabsorption. It can also be performed to
investigate ileal function, inflammatory bowel disease, chronic diarrhoea and
enterohepatic circulation. There are several causes of chronic diarrhoea and
sometimes a cause is unidentifiable following numerous investigations. Bile
acid malabsorption is one cause of chronic diarrhoea. It is not life-threatening
but can have a major impact on quality of life. It is currently the only test used
to diagnose bile acid malabsorption (NICE 2012).
Recently, SeHCAT has become available to measure BAM as an investigation
technique in this patient group in St. James’s Hospital; however there is
limited availability of this technique throughout the hospitals in the rest of
Ireland. There are multiple reasons for this; one being that it is not yet
recommended by NICE and another reason is because the SeHCAT needs to
be conducted in a nuclear medicine unit and few hospitals are equipped with
such departments. It is also quite expensive and a time consuming technique.
If there is no known cause of the patient’s chronic watery diarrhoea following
other investigations, a trial therapy of bile acid sequestrants may be
suggested.
In St. James’s Hospital, patients are now being referred for SeHCAT if they
are symptomatic with diarrhoea/steatorrhoea, where there has been no
improvement or known cause of their symptoms following surgery. This
investigation is being carried out in addition to Hydrogen breath testing in this
patient group. A new malabsorption review chart has been devised by the
Dietetic and surgical team for such patients to determine a cause of their
diarrhoea/steatorrhoea (Appendix 5).
It must be remembered that SIBO can be the cause of bile acid malabsorption
since the bacteria can deconjugate the bile acids affecting their re- absorption
in the ileum. Therefore in patients with chronic watery diarrhoea who
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demonstrate a positive HBT result post oesophagectomy and gastrectomy,
antibiotic may be trialled before the bile acid sequestrants are prescribed. This
is because the sequenstrants can have a side effect of constipation which
could possibly give a false impression in their symptom improvement of
chronic diarrhoea.
The use of HBT’s and their role in the management of patients post major
upper GI surgery looks promising. It is still an area that requires immense
research and development. With the expanding knowledge and commitment
of multi-disciplinary teams and surgical expertise, the future for patients with
difficulties post-surgery is encouraging. The GI Function Unit in St. James’s
Hospital is determined to provide a specialist testing facility for these patients
and will continue to promote and develop best practices for the future.
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Chapter 10
8 Conclusion
Lifestyle factors including smoking and drinking habits as well as BMI had a
statistically significant effect on the outcome of Hydrogen Breath Test (HBT)
results. Those patients that had either a low BMI, were non-drinkers or nonsmokers were more likely to have a positive glucose HBT.
Those patients who had a history of previous malignancy and post-operative
complications showed a higher tendency towards a positive glucose HBT
result, but this was not statistically significant.
In addition to the above statement, patients who had a longer post-operative
hospital stay following their gastrectomy or oesophagectomy also tended to
be positive for HBT using glucose substrate.
The percentage of patients positive for SIBO was greatest 6-12 months postsurgery. This may be attributed by the fact that intestinal motility including
MMC’s can take up to 12 months before it is resorted to its normal functioning
state.
The positive patient cohort tested using glucose substrate demonstrated 93%
positivity for SIBO at 60 minutes. The average time for patients to show a
positive SIBO test was 36.52 minutes.
False positive results can occur because of dumping syndrome. Therefore a
rise of >12ppm within 60 minutes is more likely to be from SIBO than colonic
fermentation of the glucose substrate.
Although some patients (up to 10%) are non-hydrogen producers, those who
are very symptomatic with negative HBT’S should be considered for bile acid
malabsorption investigation using SeHCAT.
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SeHCAT is now being used in St. James’s hospital to investigate patients who
are symptomatic with steatorrhoea/diarrhoea post-surgery. It is often
overlooked as an investigation technique but can only be performed in a
hospital with a nuclear medicine department.
SIBO can be the cause of BAM, therefore it should be considered to treat a
positive HBT with antibiotic therapy and assess clinical response before
treatment with prescribed bile acid sequestrants commences.
Recommendations:
 It is recommended that the testing protocol for glucose Hydrogen
Breath Testing is reduced from 2 hours to 60 minutes for this group of
patients if there is no rise in hydrogen levels.
 It is also recommended that symptomatic patients who have a negative
Hydrogen Breath Test be referred for a SeHCAT test.
 Further studies are recommended in a prospective group of patients to
identify SIBO pre and post treatment with both a Hydrogen and
Methane monitor.
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Glossary of Terms
Absorbent: In medical terms, are used to absorb water in the small intestine
and colon. They are used to treat diarrhoea.
Achlorhydria: Refers to the reduction or absence of gastric acid secretions.
Adsorbent: (antidiarrheal) binds to caustic bacteria and eliminates them from
the GI tract through their stool
Aerobic: (bacteria): utilize, grow and live in an oxygenated environment.
Aerophagia: the swallowing of air.
Anaerobic: (bacteria): Survive in the absence of oxygen.
Anticholinergic: a drug that blocks acetylcholine (neurotransmitter) in the
brain. In the GI tract they are used to treat e.g. diarrhoea, muscular
cramps/spasms
Arrhythmia: Irregular or abnormal heart rate or rhythm
Autonomic neuropathy: damage to the autonomic neurons. Symptoms vary
depending on the nerves affected. In the GI tract, symptoms include
diarrhoea, constipation, dysphagia, post-prandial nausea, early satiety etc.
Blind loops: can be formed as a result of surgery when part of the intestine is
by-passed. Stagnant food and slow motility makes this area a high risk
breeding ground for bacteria.
Casein: protein found in milk. Involved in the slow release of amino acids into
the bloodstream
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Chemotherapy: cancer treatment with the aim of destroying cancer cells.
These drugs can be used to treat cancer anywhere in the body because they
travel in the blood system.
Cirrhosis: occurs as a result of liver disease. Irreversible fibrous scar tissue
replaces normal liver cells.
Colonocytes: colonic epithelial cells
Colony forming units: (CFU) is an estimate of the number of viable bacterial
cells in a sample per Ml.
Co-morbidity: two or more diseases that occur simultaneously in a person with
the initially diagnosed condition.
Cytokines: (small proteins) are released by cells and are involved in cell
signalling. Their primary role is cell to cell communication in immune
responses. They can affect the behaviour of the releasing cell or other cells.
Diverticula: an out-pouching or sac formed at a weak point in the wall of the
gastrointestinal tract. Most commonly occurs in the colon
Enterocytes: epithelial cells of the small intestine
Fastidious anaerobes: organism that requires complex growth factors and
amino acids. Can survive and grow with or without the presence of oxygen
Fistula: abnormal connection between two body structures e.g. between an
artery and vein, between loops of the intestine etc.
Gastrectomy: a surgical procedure where part or all of the stomach is
removed
Gastric atony: stomach wall is lacking in tone resulting in muscle weakness
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Gastroparesis: paralysis of stomach wall resulting in poor or absent gastric
motility.
Gram positive aerobes: retains the stain used in the gram’s staining test. Can
help determine what antibiotic to use, if there is infection present, or type of
further tests required to determine cause of infection.
Hydrogen Breath Test: A technique used to measure the amount of hydrogen
in parts per million (ppm) from a sample of exhaled air
Hyperosmolar: high osmolarity especially of a body fluid e.g. occurs in
dehydration, hyperglycaemia
Hypomotility: decreased motility or movement
Ileocecal valve: a muscle valve that separates the distal part of the small
intestine and the proximal part of the colon.
Immunoglobulin: an antibody used by the immune system. Produced by
plasma cells and bind to specific antigens.
Interstitial Cystitis: a chronic and painful bladder condition.
Krebs cycle: part of cellular respiration providing energy that akes place within
the mitochondria of a cell. A series of enzyme reaction with energy being
released.
Lymphoid tissue: makes up the lymphatic system (e.g. white blood cells, bone
marrow) involved in immune response. Include organs such as the spleen,
thymus and lymph nodes.
Lysozyme: an enzyme (found in e.g. tears, salvia) that is capable of
hydrolysing bacteria by destroying their cell walls.
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Macrocytic anaemia: occurs when red blood cells are larger than normal and
there is a reduction in the number of cells. Haemoglobin content is cell is often
insufficient. This results in a reduction of oxygen reaching tissues and organs.
Mediators: a substance or a thing (e.g. enzyme or hormone) that is released
from cells to carry out a process
Myenteric plexus: a nerve supply lying in the muscular wall of the
oesophagus, stomach and intestine. Involved in the motility of the
gastrointestinal tract.
Neo-adjuvant: administration of therapy before the primary treatment e.g.
chemotherapy given before a surgical procedure.
Oesophagectomy: a surgical procedure where part or all of the oesophagus is
removed
Osteomalacia: softening of the bones usually because of a lack of vitamin D.
Radiotherapy: a cancer treatment using high energy rays to control or kill
cancer cells.
Saccharolytic: metabolism of carbohydrates for energy.
Short-chain fatty acids: produced in the colon as a result of fermentation.
Butyric acid is an important short-chain fatty acid for proving energy to
colonocytes and has anti-inflammatory/anti-carcinogenic properties.
SIBO: Small intestinal bacterial overgrowth. A condition where bacteria inhabit
the small intestine in great quantities and can induce a variety of symptoms
and other health conditions in an individual.
Tachycardia: a heart rate that is faster than the normal 60-100 bpm at rest.
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Tetany: activation of nerve cells in the body that result in spasms or cramps of
e.g. hands, feet, mouth. Usually due to low blood calcium or malfunctioning
parathyroid gland.
Viscosity: (fluid) corresponds to the ‘thickness’ of a fluid. It is a measure of the
fluids resistance to flow.
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Appendices
Appendix 1
Table A-1 - Patients tested for SIBO using Fructose and glucose solution

Patient
No.

Age

M/F

Cancer
patient

County

How long
tested
after
surgery- Surgery
mths
type

Positive
SIBO

Positive
Glucose

Positive/Fr
uctose

On
creon
y/n

Chmeo/rad
iation
Antibiotics

12 G

YES

YES

YES

NO

?

1

75 F

yes

Kilkenny

2

80 M

Yes

Dublin

6 G

NO

NO

NO

NO

?

3

48 M

Yes

Dublin

6 G

NO

NO

NO

YES

none

4

58 F

Yes

Dublin

24 G

YES

YES

YES

YES

NONE

YES

5

64 M

Yes

Wicklow

10 O

YES

YES

YES

YES

BOTH

2 Courses

6

85 F

Yes

Dublin

7 G

YES

YES

NO

?

?

7

50 M

Yes

Laois

15 O

YES

N/A

YES

YES

?

8

70 F

Yes RIP

Tiperrary

6 O

YES

N/A

YES

YES

YES

RIP

9

60 M

Yes

Wexford

6 O

YES

YES

YES

YES

?

YES

10

53 F

Yes

Wexford

5

YES

YES

YES

YES

NO

YES

11

70 M

Yes

Kildare

7 O

YES

N/A

YES

?

NO

12

67 F

Yes

Kerry

9 O

YES

N/A

YES

?

?

13

78 F

Ye

Dublin

18 O

YES

YES

YES

?

?

14

53 M

Yes

Dublin

12+ G

NO

NO

NO

YES

CHEMO

15

70 M

Yes

Dublin

24 O

NO

NO

NO

YES

?

16

52 F

No

Leitrim

6 O

YES

YES

YES

YES

?

17

70 F

Yes

Dublin

12+ O

YES

YES

YES

YES

NONE

18

79 M

Yes

Dublin

4 G

YES

N/A

YES

YES

NONE

19

53 M

Yes

Dublin

12+ O

NO

NO

NO

TRIAL
OFF

YES

20

47 M

Yes

Waterford

6 O

YES

NO

YES

TRIAL
OFF

CHEMO

21

67 F

Yes

Wicklow

9 O

YES

N/A

YES

YES

NONE

G
&DO
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NO

YES x 2

Patient
No.

Age

M/F

Cancer
patient

County

How long
tested
after
surgery- Surgery
mths
type

Positive
SIBO

Positive
Glucose

Positive/Fr
uctose

On
creon
y/n

Chmeo/rad
iation
Antibiotics

22

65 M

Yes

Dublin

4 O

YES

DNA

YES

YES

YES

YES

23

62 M

Yes

Wicklow

5 O

YES

YES

YES

YES

YES

YES

24

73 M

Yes

Galway

6 O

YES

NO

YES

YES

NO

YES

25

66 M

Yes

Donegal

9 O

YES

YES

YES

YES

NO

YES

26

54 F

Yes

Leitrim

12+ O

YES

YES

NO

NO

YES

YES

27

60 F

Yes

Louth

7 G

YES

YES

YES

YES

NO

YES

28

56 M

Yes

Dublin

7 O

YES

YES

YES

YES

CHEMO

YES

29

76 M

Yes

Dublin

G

NOT WANT

DON’T
WANT

NO

30

54 F

Tes

Limerick

15 O

NO

NO

NO

NO

YES

31

59 M

Yes

Dublin

12 O

YES

YES

YES

YES

CHEMO

DISEASE
RECURRENCE

32

72 M

Yes

Waterford

7 O

YES

YES

YES

NO

YES

NO

33

51 M

Yes

Wexford

7 O

YES

NO

YES

NO

NONE

34

48 M

Yes

Galway

7

YES

NO

YES

NO

NONE

35

83 F

no

Offaly

15 G

YES

YES

NOT WANT

YES

?

36

69 M

Yes

Clare

7 G

YES

YES

Yes

NO

CHEMO

NO

37

55 F

Yes

Longford

4 G

YES

YES

YES

YES

Chemo?

YES

38

69 M

Yes

Tipperary

12+ O

NO

NO

NO

?

YES

NO

39

74 M

Yes

Laois

7 G

YES

YES

NO

?

YES

YES

40

42 M

YES

Westmeath

6 O

YES

YES

NO

NO

Chemo

NO

41

62 M

YES

Dublin

20 O

No

No

No

?

Both

No

42

66 F

YES

Kildare

4 G

No

No

No

Yes

No

No

43

73 M

YES

Wexford

14 O

No

No

No

No

Both

No

44

71 M

YES

Waterford

12 O

No

No

No

Yes

Both

No

45

59 F

Yes

Tipperary

6 O

YES

YES

N/A

YES

NONE

? INPATIENT
STUDY

46

72 M

Yes

Waterford

4 O

YES

YES

NO

?

BOTH

?

O&G
&C
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? DISEASE
RECURRENCE

Patient
No.

Age

M/F

Cancer
patient

County

How long
tested
after
surgery- Surgery
mths
type

Positive
SIBO

Positive
Glucose

Positive/Fr
uctose

On
creon
y/n

Chmeo/rad
iation
Antibiotics

47

49 F

NO

Dublin

4 O

YES

YES

YES

?

NONE

48

65 male

yes

Westmeath

4 O

No

No

No

No

None

49

76 Male

Yes

Dublin

4 G

No

No

No

No

Chemo

RIP

50

60 Male

Yes

Waterford

4 O

YES

Yes

Yes

Yes

none

Yes x 2

51

79 Male

Yes

Longford

5 O

No

No

No

No

none

52

55 Male

Yes

Dublin

5 G

NO

NO

NO

?

Chemo

53

58 Female

Yes

Dublin

4 O

YES

YES

NO

?

Both

no

54

72 Male

Yes

Longford

4 G

YES

NO

YES

?

Chemo
(?&radio)

No; RIP

55

40 Female

Yes

Dublin

7 O

NO

NO

NO

Yes

Both

56

64 Male

Yes

Tipperary

Yes

Yes

Yes

Yes

both

57

61 Female

Yes

Meath

4 O

Yes

Yes

Yes

?

none

58

48 MALE

?

Kilkenny

24 G

No

No

No

?

?

59

47 Female

Yes

Wexford

4 G

Yes

Yes

No

No

chemo

60

79 Male

Yes

Wexford

9 G

Yes

Yes

n/a

?

Chemo

All time
splenectomy

61

72 Female

Yes

Dublin

5 G

No

No

n/a

?

Chemo

Very poor
technique

62

68 Female

Yes

Dublin

5 O

Yes

No

Yes

No

none

63

72 Male

Yes

Dublin

5 O

NO

NO

n/a

?

?

64

75 Male

Yes

Kerry

8 O

Yes

Yes

No

?

radio

65

75 Male

Yes

Dublin

5 G

No

No

No

None

none

66

67 Male

Yes

Galway

6 O

No

No

n/a

No

chemo

67

72 Female

Yes

Dublin

5 G

Yes

Yes

n/a

No

chemo

68

65 Male

Yes

Clare

5 O

No

No

n/a

No

both

RECURRENCE

69

53 Male

Yes

Westmeath

6 O

No

No

n/a

No

both

RECURRENCE

70

65 Male

Yes

Carlow

5 G

No

No

n/a

No

none

71

75 Male

Yes

Galway

6 O

No

No

n/a

No

both

O and
10 pg? and
C
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?

No

RIP

Patient
No.

Age

M/F

Cancer
patient

County

How long
tested
after
surgery- Surgery
mths
type

Positive
SIBO

Positive
Glucose

Positive/Fr
uctose

On
creon
y/n

Chmeo/rad
iation
Antibiotics

72

54 Male

Yes

Cavan

3 O

Yes

Yes

n/a

?

none

73

72 Female

Yes

Waterford

5 G

Yes

Yes

n/a

No

none

74

46 Male

Yes

Sligo

7 G

No

No

n/a

n/a

Both post
op

75

71 Male

Yes

Carlow

4 G

Yes

Yes

n/a

No

chemo

76

67 Male

Yes

Kildare

5 G

No

No

n/a

No

none

77

67 Male

Yes

Mayo

4 O

Yes

Yes

n/a

No

none

78

80 Male

Yes

Monaghan

8 G

Yes

Yes

n/a

No

none

79

61 Male

Yes

Sligo

7 O

No

No

n/a

No

none

80

50 Female

Yes

Dublin

5 G

No

No

n/a

No

Chemo
post-op

81

60 Male

Yes

Dublin

5 O

Yes

Yes

n/a

No

Chemo pre
& post

82

70 Male

Yes

Monaghan

6 O

Yes

Yes

n/a

Yes

Chemo
before

83

69 Male

Yes

Longford

27 O

Yes

Yes

n/a

No

none

84

67 Female

Yes

Dublin

6 O

Yes

Yes

n/a

?

chemo

85

58 Male

Yes

Dublin

6 O

No

No

n/a

?

none

86

74 Female

Yes

Wexford

6 G

Yes

Yes

n/a

No

none

87

51 Female

Yes

Dublin

5 O&G

Yes

Yes

n/a

Yes

chemo

88

76 Male

Yes

Offaly

5 G

No

No

n/a

No

none

89

69 Male

Yes

Donegal

5 G

Yes

YES

n/a

No

Both pre &
post

90

73 Female

Yes

Tipperary

7 O

No

No

n/a

No

none

91

74 Female

Yes

Wicklow

5 G&O

Yes

Yes

n/a

No

chemo

92

64 Female

Yes

Laois

4 O

Yes

Yes

n/a

No

both

93

59 Male

Yes

Dublin

6 G

No

No

n/a

No

Chemo

94

35 Female

Yes

Offaly

5 G

Yes

Yes

n/a

Yes

chemo

95

48 Male

Yes

Limerick

5 G

No

No

n/a

No

chemo

96

48 Male

No

Dublin

5 O

No

No

n/a

?

None
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RIP

Yes

Recurrence

Patient
No.

Age

M/F

Cancer
patient

County

How long
tested
after
surgery- Surgery
mths
type

Positive
SIBO

Positive
Glucose

Positive/Fr
uctose

On
creon
y/n

Chmeo/rad
iation
Antibiotics

97

82 Male

Yes

Wexford

4 O

No

No

n/a

?

None

98

56 Female

Yes

Monaghan

4 G

No

No

n/a

?

chemo

99

60 Female

Yes

Dublin

5 O

Yes

Yes

n/a

?

Both 2007

100

68 Male

Yes

Westmeath

4 O

No

No

n/a

No

both

101

51 Male

Yes

Sligo

5 O

No

No

n/a

No

Both pre
and post

102

71 Male

Yes

Dublin

5 G

No

No

n/a

No

Chemo

103

68 Male

Yes

Wicklow

5 O

No

No

n/a

No

both

A&e for dilo
sever dysphagia
* see notes

104

58 Male

Yes

Offaly

7 O

Yes

Yes

n/a

No

Chemo pre
& post

NOT TREATED

105

75 Male

Yes

Wicklow

10 O

Yes

Yes

n/a

?

both

106

57 Male

Yes

Wicklow

7 O

Yes

Yes

n/a

No

both
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Rrecurrence
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RECURRENCE

Appendix 2
Table A-2 - Data collection from Surgical Patient Group
Patien
t No.

Age at
Diagnosis

M/F

BMI at
diagnosis

Symptoms at Diagnosis

Smoking
status

Alcohol
Status

Positive
Glucose

1

72 F

Heartburn, epigastric pain, dyspepsia

Never
smoked

Non
drinker

YES

2

79 M

Dysphagia, Weight loss

ExSmoker

Social
Drinker

NO

3

45 M

Smoker

Heavy
Drinker

NO

4

54 F

Never
Smoked

Non
Drinker

YES

Not
Document
ed

YES

Anorexia,Epigastric pain,Lethargy,Epigastric discomfort,General
19.11 malaise,Dyspepsia

Vomiting,Anorexia,Weight loss,,Diarrhoea,Epigastric
bloating/fullness,Early satiety

5

61 M

24.62 Dysphagia

Not
Document
ed

6

83 F

19.59 Vomiting,Nausea,,Malaena,Constipation,Weight loss

Never
Smoked

Social
Drinker

YES

7

47 M

25.69 Heartburn,Epigastric pain,Odnyophagia,Dysphagia,Reflux,Other

ExSmoker

Social
Drinker

N/A

8

67 F

Anorexia,Weight loss,Epigastric pain,Dysphagia Fatigue, Chest Pain,
18.01 Anaemia

Never
Smoked

Non
Drinker

N/A

9

58 M

23.85 Reflux,Malaena

Never
Smoked

NonDrinker

YES

Not
Document
ed

YES

10

51 F

38.35 Other,Anaemia Flank pain

Never
Smoked

11

69 M

27.92 Reflux,Diarrhoea

Never
Smoked

Social
Drinker

N/A

12

76 F

16.77 Dysphagia,Reflux,Epigastric discomfort,Weight loss

Never
Smoked

Social
Drinker

N/A

13

73 F

Never
Smoked

Social
Drinker

YES

15

67 M

31.25 Dysphagia,Hoarseness,Lethargy,Anaemia,General malaise

Ex
Smoker

Social
Drinker

NO

17

65 F

24.05 Epigastric pain,Regurgitation,Nausea,Reflux

Ex
Smoker

Social
Drinker

YES

18

78 M

Anaemia

Never
Smoked

Heavy
Drinker

N/A

19

48 M

Odnyophagia,Regurgitation,Dysphagia,Reflux

Ex
Smoker

Social
Drinker

NO

20

45 M

Smoker

Social
Drinker

NO

Dysphagia,Anorexia,Weight loss

24.33 Weight loss,Dysphagia,Lethargy
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Patien
t No.

Age at
Diagnosis

M/F

BMI at
diagnosis

Symptoms at Diagnosis

Smoking
status

Alcohol
Status

Positive
Glucose

None,Other picked up on routine barretts surveillance

Never
Smoker

Social
Drinker

N/A

21

65 F

22

63 M

21.05 Dysphagia,,Diarrhoea

Ex
Smoker

Heavy
Drinker

DNA

23

61 M

Weight loss,Lethargy,Epigastric discomfort,Epigastric
18.44 bloating/fullness,Abdominal pain

Smoker

Social
Drinker

YES

24

72 M

Ex
Smoker

Social
Drinker

NO

25

64 M

31.41 None

Ex
Smoker

Heavy
Drinker

YES

26

49 F

25.81 Dysphagia

Smoker

Social
Drinker

YES

28

54 M

29.05 Weight loss,Epigastric pain,Dysphagia

Ex
Smoker

Social
Drinker

YES

Not
document
ed

Not
document
ed

NO

Ex
Smoker

Social
Drinker

YES

Ex
Smoker

Social
Drinker

YES

Never
Smoked

Social
Drinker

NO

23.1 Weight loss,Dysphagia,Reflux,Epigastric discomfort,Dyspepsia

30

52 F

Weight loss,Odnyophagia

31

57 M

32

71 M

33

50 M

36

68 M

29.12 Weight loss,Dysphagia

Ex
Smoker

Social
drinker

YES

39

73 M

32.43 Weight loss,Dysphagia,Abdominal discomfort

Ex
smoker

Non
drinker

YES

40

41 M

Vomiting,Weight loss,Regurgitation,Dysphagia,Epigastric
20.87 discomfort,Dyspepsia

Smoker

Non
drinker

YES

41

59 M

Weight loss,Dysphagia,Lethargy,Epigastric discomfort,Abdominal
35.38 discomfort

Never
smoked

Heavy
drinker

No

42

65 F

Ex
smoker

Social
drinker

No

43

71 M

Ex
smoker

Social
drinker

No

44

69 M

34.23 Reflux,Anaemia

Ex
smoker

Social
drinker

No

45

59 F

28.68 Weight loss,Dysphagia

Never
smoked

Non
drinker

YES

46

71 M

31.97 Odnyophagia,Dysphagia

Never
smoked

Social
drinker

YES

48

65 M

30.07 None
Ex

Social

20.58 Dysphagia,Weight loss

30.4 Dysphagia

Haemetemesis,Nausea,Malaena,Weakness,Lethargy,Abdominal
discomfort,Heartburn

Lethargy,Anaemia

26.5 Weight loss,Dysphagia,Weakness,Lethargy

No
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Patien
t No.

Age at
Diagnosis

M/F

BMI at
diagnosis

Symptoms at Diagnosis

Smoking
status

Alcohol
Status

smoker

drinker

Positive
Glucose

49

75 M

28.31 Reflux

Ex
Smoker

Social
Drinker

No

50

60 M

30.54 non specific chest pain

Ex
smoker

Social
Drinker

Yes

51

78 M

26.57 Weight loss,Dysphagia

Ex
smoker

Social
drinker

No

52

54 M

40.82 Heartburn,Epigastric pain,Dyspepsia

Ex
smoker

Heavy
drinker

NO

53

57 F

33.36 Weight loss,Dysphagia,Other Retrosternal pain, chest pain

Smoker

Social
drinker

YES

54

71 M

Haemetemesis,Malaena,Collapsed,Anaemia Opportunistic finding of
30.07 anaemia on investigation of shoulder injury

Ex
smoker

Social
drinker

NO

55

59 F

30.04 Dysphagia,Reflux,Dyspepsia

Ex
smoker

Social
drinker

NO

56

62 M

32.49 Odnyophagia,Hiccups,Dysphagia

Never
smoked

Social
drinker

Yes

57

60 F

Ex
smoker

Non
drinker

Yes

59

46 F

21.09 Epigastric pain,Reflux,Abdominal discomfort

Smoker

Non
drinker

Yes

60

78 M

22.43 Vomiting,Weight loss,Dysphagia

Ex
smoker

Non
drinker

Yes

61

71 F

Vomiting,Anorexia,Weight loss,Epigastric
33.24 pain,Reflux,Diarrhoea,Lethargy,Waterbrash,Abdominal pain

Never
smoked

Social
drinker

No

62

68 F

25.64 Odnyophagia,Dysphagia,Epigastric discomfort,Abdominal discomfort

Ex
smoker

Ex drinker

No

63

72 M

30.68 None

Ex
smoker

Social
drinker

NO

64

71 M

Ex
smoker

Social
drinker

Yes

65

73 M

31.67 Malaena,Anaemia

Ex
smoker

Social
drinker

No

66

65 M

38.05 Weight loss,Dysphagia

Ex
smoker

Heavy
drinker

No

67

71 F

21.08 Weight loss,Dysphagia

Never
smoked

Social
drinker

Yes

68

64 M

24.6 Weight loss,Dysphagia

Ex
smoker

Heavy
drinker

No

69

52 M

Ex
smoker

Social
drinker

No

Dysphagia

24.2

not documented

28.69 Heartburn,Epigastric pain,Regurgitation,Dyspepsia
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Patien
t No.

Age at
Diagnosis

M/F

BMI at
diagnosis

Symptoms at Diagnosis

Smoking
status

Alcohol
Status

Positive
Glucose

70

64 M

Epigastric pain,Haemetemesis,Constipation,Flatulence,Shortness of
35.54 breath,GI Bleed Haematemesis requiring 4 units of blood

Ex
smoker

Social
drinker

No

71

74 M

19.77 Weight loss,Dysphagia,Chest pain after eating

Ex
smoker

Ex drinker

No

72

58 M

26.12 Epigastric pain,Dyspepsia

Ex
smoker

Social
drinker

Yes

73

68 F

Heartburn,Regurgitation,Reflux,Lethargy,Anaemia,General
24.34 malaise,Shortness of breath

Never
smoked

Social
drinker

Yes

74

46 M

Ex
smoker

Social
drinker

No

75

70 M

Ex
smoker

Social
drinker

Yes

76

66 M

Smoker

Social
drinker

No

77

66 M

28.06 Reflux

Smoker

Ex drinker

Yes

78

79 M

42.75 Epigastric discomfort

Never
smoked

Social
drinker

Yes

79

71 M

Ex
smoker

Social
drinker

No

81

59 M

23.32 Weight loss,Dysphagia,Malaena,Anaemia,Abdominal discomfort

Never
smoked

Social
drinker

Yes

82

69 M

22.62 Weight loss,Odnyophagia,Dysphagia, Upper chest discomfort

Smoker

Heavy
drinker

Yes

83

67 M

Dysphagia,,Malaena

Ex
smoker

Social
drinker

Yes

84

66 F

22.95 Heartburn,Dysphagia,Reflux

Smoker

Social
drinker

Yes

85

56 M

31.62 Heartburn

Smoker

Heavy
drinker

No

86

71 F

17.47 Anaemia

Ex
smoker

Ex drinker

Yes

87

51 F

24.36 Weight loss,Regurgitation,Dysphagia,Early satiety

Ex
smoker

Social
drinker

Yes

88

75 M

Ex
smoker

Social
drinker

No

89

68 M

Ex
smoker

Ex drinker

YES

90

72 F

Ex
smoker

Non
drinker

No

91

73 F

Never
smoker

Social
drinker

Yes

Vomiting,Anorexia,Weight loss,Nausea,Dysphagia,Abdominal discomfort
Gastric outlet obstruction

25.55 Dysphagia,Epigastric discomfort,Cough Back discomfort

Anorexia,Weight loss,Early satiety,Abdominal pain Bloating, fullness

Heartburn ? Incidental pick up, presented to GP with subcutaneous lumps

Vomiting,Anorexia,Weight loss,Nausea,Epigastric discomfort

27.06 Epigastric discomfort

Reflux

21.11 Vomiting,Weight loss,Dysphagia,,Anaemia,Abdominal pain Back pain
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Patien
t No.

Age at
Diagnosis

M/F

BMI at
diagnosis

Symptoms at Diagnosis

Smoking
status

Alcohol
Status

Positive
Glucose

Odnyophagia,Dysphagia,Epigastric discomfort

Never
smoked

Social
drinker

Yes

92

63 F

94

34 F

Weight loss,Nausea,Dysphagia,,Early satiety Hair loss. pulsating lump in
19.93 abdomen

Never
smoked

Social
drinker

Yes

95

47 M

24.89 Weight loss,Epigastric pain,Belching,Odnyophagia,Dysphagia,Reflux

Never
smoked

Social
drinker

No

96

44 M

Heartburn,Epigastric pain,,Lethargy,Anaemia,General malaise Night
38.27 sweats

Ex
smoker

Social
drinker

No

97

82 M

26.82 Weight loss,Dysphagia

Ex
smoker

Non
drinker

No

98

55 F

Never
smoked

Non
drinker

No

99

59 F

21.71 Dysphagia,Reflux,Dyspepsia

Ex
smoker

Social
drinker

Yes

100

67 M

25.61 Weight loss,Hiccups,Dysphagia,Lethargy

Ex
smoker

Social
drinker

No

101

50 M

26.59 Vomiting,Weight loss,Epigastric pain,Dysphagia

Smoker

Heavy
drinker

No

102

70 M

29.76 Weight loss,Dysphagia,Reflux,Anaemia,Abdominal discomfort

Never
smoked

Social
drinker

No

103

67 M

Weight loss,Odnyophagia,Haemetemesis,Dysphagia,Anaemia Hb 7.5,
24.98 received 2 units blood

Smoker

Ex drinker

No

104

57 M

Smoker

Heavy
drinker

Yes

105

74 M

25.14 Weight loss,Regurgitation,Dysphagia

Ex
smoker

Non
drinker

Yes

106

56 M

33.17 Weight loss,Odnyophagia,Dysphagia,,Dyspepsia Retrosternal pain

Ex
smoker

Social
drinker

Yes

Dyspepsia,Abdominal pain

25.1 Weight loss,Hiccups,Regurgitation,Dysphagia
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Appendix 3

Figure A-1 - Example of a Negative Glucose HBT post surgery
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Figure A-2 - Example of a Positive Glucose HBT post surgery
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Appendix 4

Figure A-3 - Gastro+ Operating manual Specification Sheet

Figure A-4 - Gastro+ Operating manual Specification Sheet
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Appendix 5

Figure A-5 - Malabsorption form for post Oesophagectomy and
Gastrectomy Patients
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Appendix 6
GASTRECTOMY/OESOPHAGECTOMY QUESTIONAIRE GI Function Unit

MRN ______________________

NAME____________________________________________

DOB ___________________________

HEIGHT__________

WEIGHT__________

BMI____________

(PRE AND POST SURGERY)
DATE OF SURGERY

TYPE OF SURGERY

CHEMO/RADIATION

REASON FOR SURGERY

SYMPTOMS

ONSET OF SYMPTOMS POST SURGERY

SEVERITY OF SYMPTOMS

ANY OTHER MEDICAL HX

PRESCRIPTION MEDICATION
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Appendix 7
Publications and Presentations
•

Poster Presentation, Irish Society for Clinical Nutrition & Metabolism
2nd Scientific Conference, Clyde Court Hotel, 5th and 6th March 2013
‘Prevalence of Small Intestinal Bacterial Overgrowth Post
Oesophagectomy’

•

Poster presentations, Irish Society of Gastroenterology 50th
Anniversary, 23rd November 2012. ‘Prevalence of Small Intestinal
Bacterial Overgrowth Post Oesophagectomy’

•

Presentation ‘Hydrogen Breath Testing’ GI Physiology Day,
Conference centre, Stewarts Hospital, Palmerstown, Friday 7th
October 2011

•

Irish Society of Gastroenterology Spring meeting, Hotel Kilkenny,
29th-30th April 2010. Poster presentation ‘Hydrogen Breath Testing. A
two-year audit’.

•

Currently (2016) preparing a paper and abstract submission to the
British Society of Gastroenterology, AGM, June 2016
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